MSK  IRB#: 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(8)  
Page  1  
  
AN EXPLORATORY  RANDOMIZED  PHASE II MULTICENTER 
TRIAL OF ABIRATERONE  ACETATE WITH OR WITHOUT 
CABAZITAXEL  IN TREATMENT  OF METASTATIC  CASTRATION 
RESISTANT PROSTATE CANCER  
Prostate  Cancer  Clinical  Trials  Consortium, LLC (PCCTC) 
PCCTC LOI#: c12 -108 
Lead  Site:  Memorial  Sloan  Kettering  Cancer  Center  
Sponsor:  Memorial  Sloan  Kettering  Cancer  Center  
 
Principal  Investigator  
Susan  Slavin, MD,  PhD 
Memorial Sloan Kettering Cancer Center 
Service Chief, Genitourinary Oncology Service  
1275 York Avenue  
New  York,  NY 10021 
Slovins@mskcc.org  Statistician  
Susan Halabi, PhD 
Department  of Biostatistics  & 
Bioinformatics  
Duke  University 
Duke Box 2717  
Durham, NC 27710 
Susan.halabi@duke.edu  
 
Co-Investigator  
William  Kelly,  D.O. 
Thomas  Jefferson  University  Hospital 
Department of Medical Oncology 
1025 Walnut Street  
College Bldg., Suite 700 
Philadelphia, PA 19107 
Wm.Kevin.Kelly@jefferson.edu  
 
 
Correlative  Science  
Karen  Knudsen,  PhD 
Professor of Cancer Biology, Urology, and  Radiation 
Oncology, KCC  
233 10th Street,  BLSB  1008  
Philadelphia,  PA 19107  
Phone:  215-503-8573  
Karen.Knudsen@jefferson.edu  
MSK  IRB#: 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(8)  
Page  2  
  
 
Pathology  Collaborators  
Ruth  Birbe,  MD 
Thomas  Jefferson  University  Hospital 
1325 10th St 
Main  Building,  Suite  285A 
Philadelphia  PA 19107  
 
Rossitza Draganova -Tacheva, MD 
Thomas  Jefferson  University  Hospital 
1325 10th St 
Main  Building,  Suite  285A 
Philadelphia  PA 19107  
 
 
 
 
 
 
 
Participating  Site(s)  Principal  Investigator  Site's  Role 
Thomas  Jefferson University  William  Kelly,  D.O. Data Collection and Specimen 
Analysis  
Duke University  Susan  Halabi,  PhD Data  Analysis  
Weill  Cornell  Medical  Center  Ana Molina,  M.D. Data  Collection  
Virginia  Oncology  Associates  Mark  Fleming,  M.D. Data  Collection  
MSK  IRB#: 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(8)  
Page  3  
 
 STATEMENT  
  
 
Protocol  Date:  June  13, 2014  
 
Amended  Version  Date:  October  17, 2016  
 
 
INVESTIGATOR'S  APPROVAL  OF PROTOCOL  
 
 
 
 
 
 
Title:  AN EXPLORATORY RANDOMIZED PHASE  ll MULTICENTER TRIAL  OFABIRATERONEACETATE 
WITH  OR WITHOUTCABAZITAXEL  IN TREATMENT  OF METASTATIC  CASTRATION  RESISTANT 
PROSTATE  CANCER  
 
 
 
 
 
 
 
Principal  Investigator Signature:    
 
 
Principal  Investigator  Print:    
 
 
Date:   
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  4  
  
 
Table  of Contents  
1. INTRODUCTION,  BACKGROUND  AND  RATIONALE  ................................ ................................ ....................  6 
1.1 Disease  Background  ................................ ................................ ................................ ................................ .................  6 
1.2 Background  ................................ ................................ ................................ ................................ ................................  6 
1.3 Rationale  ................................ ................................ ................................ ................................ ................................ . 11 
2. OBJECTIVES  ................................ ................................ ................................ ................................ .................  13 
2.1 Primary  Objective  ................................ ................................ ................................ ................................ ...............  13 
2.2 Secondary  Objectives  ................................ ................................ ................................ ................................ .........  13 
2.3 Correlative  Studies  ................................ ................................ ................................ ................................ ..............  13 
3. PATIENT  SELECTION  ................................ ................................ ................................ ................................ .. 13 
3.1 Inclusion  Criteri a ................................ ................................ ................................ ................................ .................  13 
3.2 Exclusion  Criteria  ................................ ................................ ................................ ................................ .................  15 
3.3 Prohibited  Concomitant  Medications  ................................ ................................ ................................ .............  16 
4. ENROLLMENT  PLAN  AND  SUBJECT  REGISTRATION  ................................ ................................ ................  16 
4.1 Enrollment  Plan................................ ................................ ................................ ................................ ...................  16 
4.2 Registration  Procedure  ................................ ................................ ................................ ................................ ....... 17 
5. RANDOMIZATION  ................................ ................................ ................................ ................................ ....... 18 
6. STUDY  ASSESSMENTS  BY VISITS  ................................ ................................ ................................ .................  19 
6.1 Screening/Pretreatment  Assessment  ................................ ................................ ................................ ..............  22 
6.2 Day 1 of Each  Cycle  (± 7 days)  ................................ ................................ ................................ ..........................  24 
6.3 Every  3 Cycles  (Cycle  4, 7,10, ETC.,±  7 days)  ................................ ................................ ...............................  24 
6.4 Progression  on Arm l ................................ ................................ ................................ ................................ ....... 25 
6.5 End of Study  (30 Days  of Stopping  Protocol  Study  Treatments)  ................................ ..............................  25 
6.6 Correlative/Special  Studies  ................................ ................................ ................................ ...............................  25 
7. THERAPEUTIC  MODALITIES  ................................ ................................ ................................ .....................  29 
7.1 Pharmacokinetics  ................................ ................................ ................................ ................................ ..................  29 
7.2 Dosage  Selected,  Preparation,  and Schedule  of Administration  ................................ ................................  33 
7.3 Dose  Modifications  and Dose  Delay  ................................ ................................ ................................ ...............  37 
7.4 Removing  Patients  from  the Protocol  ................................ ................................ ................................ ............  43 
7.5 Concomitant  Medications  and Supportive  Care  ................................ ................................ ..........................  43 
8. SAFETY  EVALUATION  AND  REPORTING  ................................ ................................ ................................ .... 44 
8.1 Definitions  ................................ ................................ ................................ ................................ ...............................  44 
8.2 Recording  and Grading  ................................ ................................ ................................ ................................ ...... 44 
8.3 Unexpected  Adverse  Events  ................................ ................................ ................................ .............................  45 
8.4 Serious  Adverse  Events and  Serious  Adverse  Drug  Reactions  ................................ ................................  45 
8.5 Reporting  Serious  Adverse  Events  4 ................................ ................................ ................................ .................  7 
8.6 Safety  Reports  ................................ ................................ ................................ ................................ ......................  48 
8. 7 Unanticipated  Problems  ................................ ................................ ................................ ................................ ..... 48 
9. CRITERIA  FOR  OUTCOME  ASSESSMENT  /THERAPEUTIC  RESPONSE  ................................ ....................  49 
9.1 Outcome  Assessment  ................................ ................................ ................................ ................................ ...........  49 
9.2 Therapeutic  Response  ................................ ................................ ................................ ................................ ........  49 
9.3 Response  Criteria  for Control/Relieve/Eliminate  Endpoints  ................................ ................................ ... 51 
9.4 Confirmatory  Measures/Duration  of Response  ................................ ................................ ..........................  53 
10. DATA  REPORTING  AND  REGULATORY  REQUIREMENTS  ................................ ................................ ........  56 
10.1 Data  Collection  and Management  ................................ ................................ ................................ ....................  56 
10.2 Study  Monitoring  and Quality  Assurance  ................................ ................................ ................................ ..... 57 
11. STATISTICAL  CONSIDERATIONS  ................................ ................................ ................................ ..............  58 
11.1 Endpoints  ................................ ................................ ................................ ................................ ...............................  58 
11.2 Sample  Size ................................ ................................ ................................ ................................ ...........................  59 
11.3 Toxicity  Monitoring ................................ ................................ ................................ ................................ .............  59 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  5  
 11.4 Data  Analysis  ................................ ................................ ................................ ................................ .........................  59 
12. REGULATORY  AND  PROTECTION  OF HUMAN  SUBJECTS  ................................ ................................ ........  60 
12.1 Roles  and Responsibilitiies  ................................ ................................ ................................ ................................ . 60 
12.2 Ethical  Considerations  ................................ ................................ ................................ ................................ .........  61 
12.3 Regulatory  Documentation  ................................ ................................ ................................ ................................ . 61 
12.4 Protocol  Amendments  ................................ ................................ ................................ ................................ .........  61 
12.5 Additional  !RB Correspondence ................................ ................................ ................................ ..........................  63 
12.6 Written  Informed  Consent  ................................ ................................ ................................ ................................  64 
12.7 Protection  of Privacy  ................................ ................................ ................................ ................................ ..........  64 
12.8 Terminating  of Modifying  the Study  ................................ ................................ ................................ ..............  65 
12.9 Noncompliance  ................................ ................................ ................................ ................................ .......................  65 
13. REFERENCES  ................................ ................................ ................................ ................................ ................  65 
APPENDIX  A: PERFORMANCE  STATUS  CRITERIA  ................................ ................................ ...............................  68 
APPENDIX  B: MEDICATIONS  WITH  THE  POTENTIAL  FOR  DRUG -DRUG  INTERACTIONS  .............................  69 
APPENDIX  C: LABORATORY  MANUAL \CORRELATIVE  STUDIES  ................................ ................................ ....... 70 
APPENDIX  D: SOP FOR  ULTRASOUND \CT-GUIDED  BIOPSY  ................................ ................................ ..............  71 
APPENDIX  E: LISTING  OF EXPECTED/UNEXPECTED  ADVERSE  EVENTS  ................................ .........................  72 
APPENDIX  F: GLOSSARY  OF ABBREVIATIONS  AND  ACRONYMS  ................................ ................................ ...... 75 
APPENDIX  G. PILL  DIARY  ................................ ................................ ................................ ................................ ........  79 
APPENDIX  H: STANDARD  OPERATING  PROCEDURE  FOR  SHIPMENT  OF CLINICAL  SAMPLES  ....................  80 
APPENDIX  I: 1ST SAE  REPORT  ................................ ................................ ................................ ............................  811 
APPENDIX  J: PCCTC  SERIOUS  ADVERSE  EVENT  REPORT  FORM  ................................ ................................ ....... 82 
APPENDIX  K: PCCTC  BONESCAN  ASSESSMENT  TOOL  ................................ ................................ ........................  83 
APPENDIX  L: HALABI  NOMOGRAM  (UPDATED  ASCO  2013)  ................................ ................................ ...............  84 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  6  
 
 
 
1. INTRODUCTION,  BACKGROUND  AND  RATIONALE  
1.1 Disease  Background  
Every year in the United States 28,000 men die of metastatic prostate cancer.8 Since the 
introduction  of hormonal  therapy sixty years ago,9 progress  in developing  new treatments 
has been poor.10 The biological revolution of the  past two decades has produced few useful 
targeted agents against prostate cancer. In 2012, metastatic prostate cancer remains a 
uniformly  fatal disease.  It is striking that while  molecular  subtyping  has afforded 
therapeutic benefit and improved patient survival in other tumor types,11-14 no comparative 
advances have been gained in the context of prostate cancer.  At present, all patients with 
metastatic  prostate  cancer are  treated  identically, and there are  no means with  which  to 
select appropriate therapeutic regimens based on tumor profiling.  
The course of prostate cancer from diagnosis to death is best categorized  as a series of 
clinical states (Figure 1). These clinical states involve the co mplex interplay of a network of 
signaling molecules that collectively promote net cell proliferation  relative to cell death.  
Treatment  options  for patients  with castrate  resistant  prostate  cancer  (CRPC)  are limited 
and until recently only docetaxel was shown to improve survival. In the  last year we had 4 
new agents; abiraterone  acetate, cabazitaxel,  enzalutamide  and Sipuleucel -T approved  for 
use in this clinical state. However the optimal sequencing of these agents is unknown. 
Moreover all patients with CRPC are  treated identically  and there is no  means of identifying 
which patient population would benefit from a particular agent.  
Figure  1. Clinical states  of prostate  cancer  
1.2 Background  
This study is based on robust in vitro,  in vivo,  and clinical findings that have been reported. 
First,  loss of retinoblastoma tumor suppressor (RB) function was recently identified as a 
major means by which castration -resistant tumors develop.  Up to 60% of  CRPC tumors 
examined to date  show  loss of RB  function.  Second.  modeling  this event  in human xenografts 
demonstrated  that loss of RB is sufficient  to drive  the transition  to castration  resistance. 
The underlying mechanisms by  which RB  loss promotes CRPC  were  illuminated, whereupon 
it was revealed that expression of the  androgen receptor (AR) is under stringent RB  control. 
Consonantly, loss of RB results in AR deregulation and bypass of androgen deprivation 
therapy, and investigation of human  CRPC revealed that this occurrence is frequent in the 
clinical setting. Third , while RB -deficient tumors are resistant to androgen deprivation 
therapy, tumors lacking RB are  compromised for DNA damage checkpoints that normally 
allow  for repair  after  genom ic insult.  As a result,  tumors  devoid  of RB function  are 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  7  
 
 
 
hypersensitive to treatment with agents that induce genotoxic stress. These collective 
findings strongly support the novel  hypothesis  that leveraging RB status to  tailor 
treatment for  CRPC  will improve  outcomes for  advanced disease.  
 Loss  of RB function is  a major  effector  of the transition to  advanced  prostate cancer:  The RB 
tumor suppressor protects against tumor development in a large number of  tissues; 
accordingly, RB function is ablated in early  stages as a function of tumorigenesis in several 
human malignancies (e.g. breast, cervical and small cell lung  cancer).15,16 
The function of  RB in protecting against tumor development  is manifest through  the ability 
of this protein to act  as a transcriptional repressor, binding to the regulatory region of genes 
whose functions are important for cell cycle progression and DNA replication. Recent  
interrogation of RB function in human prostate cancer does not fit this paradigm, and deep 
investigation illuminated five key features of RB action that have a significant impact on 
disease progression and therapeutic intervention:  
1.2.1  Knudsen and colleagues  at Thomas  Jefferson University observed in clinical specimens 
that RB expression (mRNA or  protein) is retained  in primary disease.1 
This premise was further validated by analyses of RB function and they have 
developed a unique mRNA "signature" using genet ically modified tissues that 
accurately assesses RB  function in  any cell type.1,2  
Such  analyses  are critical,  as tumors retaining  RB expression can  be devoid  of RB 
function,  as occurs  through  mutation  of RB and or factors  that induce  excessive  RB 
phosphorylation (thus suppressing RB tumor suppressor activity). They have 
further refined this gene signature (unpublished data), and recently developed a 
high density  microarray  chip that provides  a robust  measure  of RB function built  off 
of an FDA  approved  Affymetrix  platform  in accordance  with GMP/GLP  (Figure  2). 
For this proposal,  RB status  will be determined  using  immunohistochemistry  but an 
accompanying,  exploratory  endpoint  will be to  assess  clinically whether  the RB chip 
can be used  to assign  RB functional  status  from  tissue  and circulating  tumor  cells.  
 
Figure 2. Development of the RB loss signature microarray chip. A refined version of the  published RB loss -of­ 
function  gene  expression  signature  was recently  developed  into a proprietary  high density  microarray  chip 
(middle  panel)  that provides  faithful  measure  of RB function . The right  panel  provides  examples  of data 
obtained  from  3 samples  that retain  RB function  vs. 3 from  tumors  wherein  RB function  has been  suppressed.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  8  
 
 
 
1.2.2 Using  multiple  methods  to assess  RB expression and activity,  it was noted that  RB loss 
of Junction  is highly  overrepresented  in CRPC.  
A representative example of the  data are shown in Figure 3 and in the study  by 
Sharma et al. 1 
Using the  combined analyses of RB expression and the RB signature, up to 60% of 
CRPCs show loss of RB activity. While the initial study examined over 150 CRPC 
specimens,  enrichment  of RB loss  in the CRPC setting  has been  further  confirm ed by 
the work  of Gerald  and Sawyers,17 and in subsequent  analyses  of cohorts  from  Dr. 
Tapio Visakorpi (data not shown).  Moreover, recent mouse models confirm the 
importance of RB in prostate cancer.18 
 
 
Figure  3. RB function  is perturbed  in the transition  to CRPC.  These  data are taken  from  a recent  comprehensive 
study (Sharma  et al.,  J Clin Invest 2010) which assesses RB functional status in multiple tumor  sets. As 
shown, the RB loss  signature is  highly overrepresented in CRPC (left) . Quantification  and statistical analyses 
(right)  demonstrate  that there  is little  evidence  for loss of  RB function  in primary  disease,  whereas  this event  
is frequent  in CRPC.  Based on  this published (Sharma et  al., 2010)  and new  preliminary data,  analyses  of over 
150 CRPCs demonstrate that RB  loss of function occurs in up  to 60% of CRPCs . 
1.2.3  Modeling  of RB loss in  multiple human  xenografts  unexpectedly  revealed  that ablation 
of RB function does not induce a significant tumor  growth advantage  prior to hormone 
therapy,1 thus indicating  that in this tumor type, RB  plays a  role distinct from that in 
other tis sues.  
Strikingly, in vivo castration challenge revealed that RB -deficient tumors are 
exquisitely  resistant  to castration  therapy.  A representative example  of these  data 
are shown in Figure 4  and in the article by  Sharma et al.  1 
These  observations were the first to suggest that in prostate cancer, RB serves a 
unique role  to protect  against the transition to  lethal disease.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  9  
  
 
 
 
Figure 4. RB loss is sufficient to drive the transition to CRPC. Ablation of RB in human  prostate cancer 
xenografts  is sufficient  to render  castration  resistance.  An example  is provided  here, wherein  isogenic  pairs  
of human xenografts were examined +/- sh RNA directed against  RB. RB ablation alone had  no effect on 
tumor growth in the  pre-castration setting (not shown but provided in 1), whereas RB depletion strongly 
promoted  castration -resistant  growth  (left) and a shorter time to biochemical  failure serum  PSA (right) . 
 
 
1.2.4.   The underlying  mechanisms  of RB Junction  were  further  explored,  whereupon  it was 
discovered  that expression of the  gene  encoding the  AR is under RB  control.  
These data are extensive and not shown herein due to space limitations.  Please see 
the recent  study inf.  Clin. Invest.,1and resulting commentary article inf  Clin Invest.19 
In brief, loss of RB caused de -repression of the  AR locus, excessive AR production, 
and castration -resistant (ligand independent) AR activity that proved sufficient to 
bypass hormone therapy. Thus, means to r estore RB function would be of a 
significant therapeutic benefit.  
 
1.2.5.   Finally,  RB status  proved  strongly  predictive  of surviva/,1as  was confirmed  using 
multiple cohorts.  
An example  of these  data is shown in  Figure  5. 

MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  10  
  
 
 
 
Figure 5. RB loss  of function is associated with poor outcome. As was 
shown and described in detail the RB loss signature is associated with 
poor outcome, including a shorter time to recurrence free survival.  
Combined, these data identify RB  tumor  suppressor activity is  critical to 
determine the  outcome and possible treatments for patients with  castrate 
resistant prostate cancer.  
1.2.6.  Treatment of RB -deficient tumors:  leveraging the loss of DNA damage checkpoints for 
clinical benefit  
Studies demonstrate that RB -deficient tumors acquire hyperactive AR activity and 
bypass  first line  hormone  therapy.  By contrast, it has  been  shown  in multiple 
models of disease that RB -deficient cells lack cell cycle checkpoints that induce cell 
cycle arrest after genomic insult. 1-3 
Thus, in model systems, RB -deficient tumor cells are  hypersensitive to agents that 
induce genotoxic stress (including etoposide, radiation, and  taxanes). Examples in 
fibroblasts and prostate cancer cells are shown in Figure 6. Furthermore, it was 
recently observed in breast cancer that patients harboring RB -deficient tumors  
showed improved survival upon treatment with chemotherapy.20 
Based on the se findings, it is anticipated that stratification of patients with RB­ 
deficient tumors into chemotherapy containing regimens will afford significant 
clinical benefit.  

MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  11  
  
 
 
 
Figure  6. RB deficient  tumors  are hypersensitive  to a subset  of DNA  damaging  and chemotherapeutic  agents.  
A. Early studies in fibroblasts revealed that RB -deficient cells are  compromised  for a subset of DNA 
damaging  checkpoints  and become  hypersensitive  to treatment  with agents  that induce  genotoxic  stress.21 
For example,  fibroblasts  deficient  in RB are hypersensitive to  cisplatin . Subsequent  analyses  revealed  that 
the hypersensitization events are tissue specific . B. In vivo analyses show that RB deficient human prostate 
cancer cells are  hypersensitive to ionizing  radiation . C. Initial screening agents, wherein  isogenic  pairs of 
RB+ and RB - cells were treated with chemotherapeutics revealed that RB -deficient cells are  also 
hypersensitive to microtubule poisons.  These preliminary studies en tailed only a brief exposure to low dose 
chemotherapy, so as to  identify meaningful  changes in  survival that  could  be refined through  multiple dosing . 
1.3 Rationale  
The clinical  dilemma  that faces  physicians  once  a patient  relapses  from primary  hormonal 
therapy is whether to initiate secondary endocrine therapies such as anti­ 
androgens/androgen  biosynthesis inhibitors  or move  directly  to chemotherapy.  Currently, 
there are no biomarkers to help us identify patients that may still  be androgen receptor 
sensitive and many  clinicians will use a  trial and error approach to patients thus delaying 
patients  from receiving  chemotherapy  in a timely  manner.  Methods  to distinguish  androgen 
receptor  sensitive  vs. insensitive  patients  would  greatly personalize  the approach  of CRPC 
and is an unmet clinical need.  
Recently, the drug abiraterone acetate, a 17 lyase inhibitor, has shown to improve the 
survival of CRPC patients that have failed docetaxel based chemotherapy.4 While 
abiraterone acetate has recently received FDA approval for CRPC that have failed prior 
docetaxel chemotherapy, more recently abiraterone acetate has shown clinical benefit in 
the pre -chemotherapy setting (RB+ and RB - tumors). Abiraterone acetate impr oved 
radiographic progression -free survival (16.5 vs. 8.3 months, hazard ratio 0.53, p<0.001) 
showed a trend toward improved overall survival, and significantly delayed initiation of 
chemotherapy  in patients  with metastatic  castration -resistant  prostate  cancer.  Based  on the 
cumulative  data on abiraterone  acetate,  the FDA  has approved  the use in pre-chemotherapy 
setting.s  
Abiraterone  acetate is a safe drug and the  most common  side effects  of the  medication 
appear to be hypertension,  hypokalemia and fluid retention which are likely from excess 
mineralocorticoid secretion, which are mostly corrected with the concomitant use of 
prednisone. Most other adverse events (AEs) were Grade 1 or  2 toxicities in prior studies. 
Due to the  ease of administration,  the recent  results showing  clinical  benefit in CRPC  prior 
to chemotherapy  along with  its favorable  safety profile,  it is expected  that abiraterone 
acetate  will be used  extensively  prior to chemotherapy.  However,  there  is still a substantial  

MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  12  
  
 
proportion  of patients  that do  not clinically  respond  to abiraterone  acetate  treatment  and 
pre-clinical studies suggest that these tumors may have a RB deficient phenotype as  
described above. Thus, these patients may benefit from earlier chemotherapy.  
Docetaxel is the standard chemotherapy in the first line setting for CRPC.22 Cabazitaxel is a 
more potent micro -tubule inhibitor that has improved overall survival in CRPC patients that 
have failed docetaxel chemotherapy when compared to mitoxantrone.6 Cabazitaxel's most 
common side effects are  hematological with the dose limiting  side effect being neutropenia. 
Other Grade 3 toxicities noted were diarrhea, fatigue, asthenia and back pain. Febrile 
neutropenia was observed in 8% of patients in the second line setting. A head to head 
comparison of docetaxel and cabazitaxel is ongoing; but it is generally considered that 
cabazitaxel will be equivalent or better than docetaxel in the first line setting. Therefore, it 
would  be reasonable  to consider  a combination  of abiraterone  acetate  and cabazitaxel  in 
this setting given the  non- overlapping toxicities.  There is a  phase I \II trial of cabazitaxel 
and abiraterone acetate in patients th at have progressed  after treatment with docetaxel  
(Sanofi sponsored study, [STUDY_ID_REMOVED]). This study has completed dose escalation part of 
the study where 2 dose levels of cabazitaxel, 20 and 25 mg/m2 IV every 3 weeks, were 
administered with abiraterone ace tate 1000 mg daily and prednisone 5 mg po BID. The 
maximal tolerated dose was established at cabazitaxel 25 mg/m2 dose level without dose 
limiting toxicities in  6 evaluable patients (personal communication Massard et al.; abstract 
submitted ASCO 2013).  
This is an exploratory randomized phase II trial of abiraterone acetate \prednisone (AA) 
alone followed by cabazitaxel on progression of disease versus the combination of 
abiraterone  acetate  and cabazitaxel (AA+C) upfront  in patients  with chemotherapy nai've 
CRPC. Since little is known about the RB status in patients treated on prior trials with 
abiraterone  acetate  or chemotherapy,  the RB  status  of all patients  will be determined prior 
to treatment at study entry to help develop a possible marker that may help select 
treatment  in the future.  In this study,  the RB  status  will not be used  to determine  treatment 
but to determine the feasibility in assessing the RB status in patients and to predict the 
prevalence of the  RB positive and  negative tumors in patients treated with abiraterone 
acetate \prednisone  or abiraterone acetate \prednisone + cabazitaxel.  This will allow us  to 
understand the effects of treatment in these populations and in the future could identify 
patients  that may bene fit from  chemotherapy  earlier. While,  this technology  for RB profiling 
has shown robust results in the laboratory, this will be the first trial to determine RB 
profiles  prospectively  in patients  and data from  this trail will help guide  future  randomized 
trials  that can be designed  to evaluate  the utility  of RB status  in patients  with CRPC.  
 
In summary, this study is a non -comparative randomized trial to 1) extend the  pre-clinical 
work on RB status in prostate cancer to patients, 2) explore the feasibility of determine RB 
status in patients tumors and circulating tumor cells, 3) to determine the prevalence of RB 
status  in prostate  tumors  that are chemotherapy  nai've,  4) to determine  the safety and 
clinical outcomes in chemotherapy nai've prostate cancer with the combination of AA + C, 
and 5) correlate the clinical outcomes based on RB status and treatment in patients. The 
information derived from this study is critical for the development of RB as biomarker and 
designing \powering future studies that will help select those patients that will need 
chemotherapy in their disease course.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  13  
  
 
2. OBJECTIVES  
2.1 Primary  Objective  
1. To determine the radiographic progression  free survival (rPFS) of abiraterone 
acetate \prednisone with and without cabazitaxel  in patients with chemotherapy  naive 
CRPC.  
2.2 Secondary  Objectives  
1. To determine PSA  progression free  survival (PSA  PFS)  in patients  treated  with 
abiraterone acetate \prednisone with and without cabazitaxel in patients with 
chemotherapy naive CRPC  
2. To determine  the proportion  of chemotherapy  naive  CRPC  patients  with measurable 
disease  regression  based  on RECIST  treated  with abiraterone  acetate  with and without 
cabazitaxel.  
3. To determine  the overall  toxicity  and survival of  abiraterone acetate  with and without 
cabazitaxel  in patients  with chemotherapy  naive  CRPC.  
4. To determine the proportion of patients that have  an objective response by RECIST and 
post-therapy PSA decline using a waterfall  plot in patients that are treated cabazitaxel 
after  progression  on the abiraterone \prednisone alone arm  
2.3 Correlative  Studies  
1. To prospectively estimate  the proportion  of patients  that have  tumors  that are RB 
negative \positive  based  on immunohistochemistry and  RB gene  signature  from  the 
baseline tumor biopsy samples.  
2. To determine the  feasibility of obtaining the RB  status  for prostate cancer on  circulating 
tumor cells at baseline.  
 
3. PATIENT  SELECTION  
3.1 Inclusion  Criteria  
Patient  needs  to have  a histologic  or cytologic  diagnosis  of prostate  cancer  
3.1.1 Documented progressive  metastatic CRPC based on  at least one  of the  following 
criteria:  
a) PSA  progression  defined  as 25%  increase  over baseline  value with  an increase 
in the absolute value of at least 2 ng/mL that is confirmed by another PSA level 
with a minimum of a  1 week inte rval and a minimum PSA  of 2 ng/mL.  
b) Soft-tissue progression defined as an increase  20% in the sum of the  LD of all 
target lesions based on the smallest sum LD since treatment started or  the 
appearance of one or more new lesions.  
c)  Progression of bone disease (evaluable disease) or (new bone lesion(s)) by bone 
scan.  
3.1.2 Agree to undergo a biopsy of at least one metastatic site or primary prostate for 
determination  of the RB status.  Adequate  archival  metastatic  tissue  can be used  if 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  14  
  
 
available  in lieu of a biopsy  if done  when  patient  had CRPC  (within  6 months  of 
treatment  start).  
3.1.3 ECOG  performance  status  of0-2. 
3.1.4 Age 18years.  
3.1.5 Have  testosterone  < 50 ng/dL.  Patients  must  continue  primary  androgen 
deprivation with an LHRH/GnRH analogue (agonist or antagonist) if they have not 
undergone orchiectomy.  
3.1.6 Patients on long term (>6 months) anti -androgen therapy (e.g. flutamide, 
bicalutamide, nilutamide) will need to be off anti -androgen for 4 weeks (wash out 
period)  and show evidence  of disease  progression  off the anti-androgen. Patients 
that have been on an anti -androgen 6 months or less will need to discontinue anti­ 
androgen  therapy prior to treatment start (no wash out  period  required).  
3.1.7  Patients must have adequate organ and marrow function as defined below obtained 
within 14 days prior to treatment start:  
 
 
 
ANC  
Hemoglobin  
Platelet count 
Creatinine 
Potassium 
Bilirubin 
SGOT (AST)  
SGPT  (ALT)  1,500/µl  
9g/dL 
100,000/µl  
s; 1.5 x the institutional  upper  limit  of normal (ULN) 
within institutional range  
s; ULN  (unless  documented  Gilbert's  disease)  
:-::; 2.5 x ULN 
 
:-::; 2.5 xULN 
 
 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  15  
  
 
3.1.8 The effects  of cabazitaxel  and abiraterone  acetate  on the developing  human  fetus  at 
the recommended therapeutic  dose  are unknown.  Men  must  agree  to use adequate 
contraception prior  to study  entry,  for the duration of  study  participation and  for at 
least 3 months thereafter.  
3.1.9  Patients  must be able to take oral medication  without crushing, dissolving or 
chewing tablets.  
3.1.10   Patients may  have received prior radiation therapy or major  surgery.  However,  at 
least 21 days prior to treatment start must have elapsed since completion of 
radiation therapy or major surgery and patient must have recovered from all side 
effects at the time of randomization.  
3.1.11  Ability to understand and the willingness to sign a writ ten informed consent 
document that is approved  by the  local institutional review board.  
3.2 Exclusion  Criteria  
3.2.1  Patients may not be rece1vmg any other investigational agents. Any prior 
investigational therapeutic products must be stopped at least 28 days (4  week 
washout)  prior to treatment start.  
3.2.2 No prior exposure  to abiraterone  acetate  or other  specific  CYP -17 inhibitors.  
3.2.3  No prior chemotherapy regimen.  Prior isotope therapy with Strontium -89, 
Samarium  or RAD223  should  be completed  at least  three  months  (12 weeks)  prior 
to treatment start.  
3.2.4 No ;:: grade  2 peripheral  neuropathy  
 
3.2.5  Patients who have had antifungal agents (itraconazole, fluconazole) within 4 weeks 
prior to treatment start or those who have not recovered  from AEs due to these 
agents administered  more than 4 weeks earlier.  
3.2.6  Patients with a history of pituitary or adrenal dysfunction,  active or symptomatic 
viral hepatitis or chronic liver disease are not eligible.  
3.2.7  Patients with known symptomatic brain metastases should be  excluded from this 
clinical trial because of their poor prognosis and because they often develop 
progressive  neurologic dysfunction  that would  confound  the evaluation  of 
neurologic and other AEs.  
3.2.8  History of allergic reactions attributed to  compounds of  similar chemical or biologic 
composition to cabazitaxel or other drugs formulated with polysorbate 80; or 
abiraterone acetate.  
3.2.9  Patients  may continue on  a daily  Multi -Vitamin,  calcium and  Vitamin D,  but all other 
herbal, alternative and food supplements (i.e. PC -Spes, Saw Palmetto, St  John Wort, 
etc.) must be discontinued before treatment start.  Patients must not be planning to 
receive any  concurrent cytotoxic chemotherapy, surgery for their prostate cancer,  or 
radiation therapy during protocol treatment.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  16  
  
 
3.2.10   Patients  on stable  doses  of bisphosphonates  or the RANK -L inhibitor,  Denosumab, 
which  have  been  started  no less than 4 weeks  prior  to treatment  start,  may continue 
on this  medication, however patients are not allowed to initiate 
bisphosphonate/Denosumab therapy during the study.  
3.2.11   Uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection, symptomatic congestive heart failure (New York Heart  Association Class 
III and IV heart failure), unstable angina pectoris, cardiac arrhythmia, or psychiatric 
illness/social situations that, in the opinion of the investigator, would limit 
compliance with study requirements or concurrent medications that alt er cardiac 
conduction.  
3.2.12   Patients with a "currently active" second malignancy other than non -melanoma skin 
or superficial  urothelial  cancers are  not eligible. Patients  are not considered  to have 
a "currently active" malignancy if they have  completed therapy and are now 
considered without evidence of disease for 2 years.  
3.3 Prohibited  Concomitant  Medications  
• Chemotherapy  
• Immunotherapy  
• Radiopharmaceuticals  like Strontium  or Samarium  or Radium -223 
• S alpha  reductase  inhibitors  
• Spironolactone  
• Diethy -Stilbestrol  
• Ketoconazole  
• Newer  medications  targeting androgen  receptors.  
Because of the  potential for drug -drug interaction, the concurrent  use of all other drugs, 
over-the-counter medications,  or alternative  therapies  must be  documented  on the  case 
report form (CRF). The principal investigator should be alerted if the  patient is taking any 
agent which interacts with CYP450 system as  found in  Appendix B (a  listing  of medications 
with the potential for drug -drug interactions).  
4. ENROLLMENT  PLAN  AND  SUBJECT  REGISTRATION  
 
4.1 Enrollment  Plan  
4.1.1 Participating  Study  Centers  
This study  is anticipated  to be  conducted  in S site(s).  
4.1.2 Recruitment  
Potential  research subjects will  be identified  by a member of the  patient's  treatment  team, 
the protocol investigator, or research team at participating centers from Medical Oncology, 
Radiation Oncology and Urology offices. Investigators will screen the patient's medical 
records for suitable research study subjects and discuss the study and  their potential for 
enrolling in the research study.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  17  
  
 
4.2 Registration  Procedure  
After eligibility screening and confirmation that a patient is eligible, patients who are 
selected  to participate  will be registered  with the PCCTC  Caisis  EDC,  the PCCTC's  Clinical 
Data  Management  System (CDMS).  A record  of patients  who fail to meet  eligibility  criteria 
(i.e., screen failures) will be maintained. Patient registration must be complete before 
beginning any treatment or study  activities. A complete, signed study consent and HIPAA 
authorization are required for registration.  
4.2.1 Registration  
• Confirm  eligibility  as defined in  Section  3 Patient  Selection.  
• Obtain informed consent, by  following procedures in  Section  12.6 Written 
Informed Consent.  
• Obtain  completed  or partially  completed protocol  specific  Eligibility 
Checklist.  
• All participants will be  registered through PCCTC Caisis EDC,  the PCCTC's 
CDMS.  
Central  registration for  this study  will take place  at MSKCC.  To complete  registration 
and enroll a participant, the study staff at that site must contact the designated 
research  staff at the PCCTC to  notify  him/her of  the participant registration.  The site 
staff then needs to email registration/  eligibility checklist and source documents to  
the PCCTC at  PCCTC@mskcc.org .  (Note:  Source  documentation of  eligibility  is 
not required for MSKCC participants.)  
These  documents  must  be sent for each  enrollment  within  24 hours  of the 
informed consent form being signed.  
Upon receipt, the research staff at the  PCCTC will  conduct  an interim review  of all 
documents for  all non-MSKCC participants.  If the eligibility  checklist  is not 
complete or  source documentation is missing, the patient will be registered pending 
enrollment and the site is responsible for sending the completed registration 
documents within 30 days of the  consent.  
If the external  registration  submission  is comple te, the participating  site IRB has 
granted  approval  for the  protocol, and the site has been activated  by MSKCC, the 
PCCTC will register the participant non -MSKCC  participants. MSKCC participants 
will be fully registered by MSKCC.  
Once the  participant is registered, the participant will be  assigned a PCCTC Caisis 
Subject ID.  This number is unique to the participant and must be  written on  all data 
and correspondence  for the participant.  This PCCTC Caisis  Subject ID will be 
relayed back to  study  staff at the  registering site via e -mail and will serve as the 
enrollment confirmation. This number is unique to the participant and must be 
written  on all data and corresponde nce for the  participant.  
Participating sites will register subjects locally per their Institutional guidelines and 
the PCCTC  will register  all non-MSKCC  participants  with MSKCC's Protocol  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  18  
  
 
Participant Registration (PPR) Office per MSKCC's guidelines. MSKCC participants 
will be fully registered by MSKCC with PPR.  
4.2.2 Institutional  Registration  
Patient registration at each study site/institution will be conducted according to the 
institution's established policies. Patients must be registered with the PCCTC, 
MSKCC and their local site/institution before beginning any treatment or study 
activities . 
At MSKCC,  all participants must  be pended  with MSKCC's  Protocol Participant 
Registration (PPR) Office prior to  submitting registrations to  the PCCTC.  
The PCCTC  will register  all non-MSKCC  participants with  MSKCC's Protocol 
Participant Registration (PPR) Office per MSKCC's guidelines.  
MSKCC will  register  all MSKCC participants with MSKCC's Protocol Participant 
Registration Office (PPR) per MSKCC's guidelines.  
 
5. RANDOMIZATION  
This is a randomized  phase  II trial in which  80 patients  will be randomized  with equal 
probability to  one of two possible treatment regimens: abiraterone acetate \prednisone 
(AA)  or AA plus cabazitaxel  (AA+C). The  randomization  will be stratified  by Halabi 
nomogram  (Appendix  L) based  on low (defined  as ( 166.6  points  in the nomogram)  or high 
risk(>166.6  total points)7.  Patients  will be randomized after  the investigator has  verified 
that all eligibility  criteria  have been  met and the patient  is registered to  the study.  Patients 
will be randomized to  receive  abiraterone  acetate \prednisone  (AA) (Arm  1) or  AA plus 
cabazitaxel  (AA+C)  (Arm  2) in a 1:1 ratio.  
Accrual is  expected to be  completed within 2  years  after trial  activation at participating 
sites.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  19  
 
- 
- 
-  
 
6. STUDY  ASSESSMENTS  BY VISITS 
 
 
 
 
• Informed  consent  and research  
I  
 
 
 
 
 
Dayl   
 
 
 
 
 
Dayl   
 
 
 
 
 
Dayl   
 
 
 
 
and etc  - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CT\MRI  of the chest  or CXR,  
abdomen  and pelvis,  and X X X 
radionuclide  bone scanc  
I Tumor  Measurementc  X X X 
 
CBC, differential, Platelets0 
Serum Chemistry (see Lab/ 
Correlatives  Studies  Manual)  
Liver Function Tests E 
PSA 
Serum Testosterone 
Serum Triglycerides  X X X 
X X X 
X XE XE 
X X X 
X 
X X X X 
X X X 
XE XE X 
X X X 
X 
X 
 
Tumor  Biopsy F X XH 
Circulating  Tumor  Cells  by EPICG  X X X 
Androgen  PanelM  X X X  Arm1   
Abiraterone acetate  1000 mg  po 
daily+ prednisone 5 mg po BID  Screening  
Within 28 days  Within  14 days 
of treatment  of treatment  
start  start  One Cycle=  3 Weeks  (21 days)A  
Cycle  1 Cycle  2 Cycle  3 Cycle 
4, 7, 10  
EQSK  I 
 
        
 
authorization/  HIPAA  form  X       
Demographics,  medical  history, 
histologic and radiologic 
confirmation of disease   
X       
Physical  examination,  vitals,  
weight,  blood  pressure8  X X X X X X 
Height   X      
Karnofsky  or ECOG performance 
status   
X X X X X X 
Halabi  Nomogram  Risk  
X      
EKG   X      
Concomitant  medications  X  X X X X X 
Toxicity/Adverse  Event  
assessments    X X X X X 
 

MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  20  
 
, - 
X 
- , 
X  
 
I Plasma  for cDNA  I X X X 
 
Abiraterone/Prednisone  
CabazitaxelI  
 
Arm 2: 
Cabazitaxel  25 mg/m2  IV every  3 Screening  One Cycle=  3 Weeks  (21 days)A  
weeks  + abiraterone  acetate  1000 
mg po daily + prednisone 5  mg Within  28 days 
of treatment  Within  14 days 
of treatment  Cycle  1 Cycle  2 Cycle  Cycle 
10, 13, EOSK  
po BID start start  Dayl  Day 1 3-9 
and etc - 
Informed  consent  and research  X 
authorization/  HIPAA  form  
Demographics,  medical  history,  
histologic  and radiologic  X 
confirmation  of disease  
Physical  examination,  vitals, 
weight, blood pressure8 
Height  
Karnofsky  or ECOG performance 
status  
Halabi  Nomogram  Risk 
EKG   
 
 
X X X 
 
X 
X X X 
X 
X  
 
 
X X X 
 
 
X X X 
Concomitant  medications  X 
Toxicity/Adverse  Event 
assessments  X X X 
X X X 
X -X 
CT\MRI  of the chest  or CXR,  
abdomen  and pelvis,  and X 
radionuclide  bone scanc  C4,C7  X X 
I Tumor  Measurementc  X 
 
CBC, differential, Platelets0 
Serum Chemistry ( see Lab / 
Correlative Studies Manual) 
Liver Function Tests E 
PSA 
Serum Testosterone 
Serum  Triglycerides   
 
 
xo X 
X X 
X XE 
X X 
X 
X C4,C7  X X 
 
X X X X 
X X X X 
XE XE X X 
X X X X 
X 
C4,C7  X X' X -------------------------------- -- X r 
! 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  21  
 
 
 
 
b 
 
 
p 
s 
y 
Arm 1: 
Abiraterone \Prednisone  - 
- 
A: All visits  have  a window  of± 7 days 
B: Patients  are to be encouraged  to measure  blood  pressure  weekly . 
C: CT scans/MRI (to  follow measurable disease)  and bone  scans  (to follow  bone  disease)  are required every 3  cycles beginning  on Cycle  4 until  evidence  of 
progression or relapse . Patients who have received a  chest CT (or MRI) need  not have  a chest  x-ray. Scans may be  done up  to ±7  days prior to beginning a 
cycle . Confirmatory  scans  should  also be  obtained  at least  4 weeks following  documentation  of objective  response . End of Study scans  can be performed± 
30 days from End of Study Visit  
D: During the first cycle of cabazitaxel  therapy, CBC will  be obtained  weekly . CBC: White  blood cells count (WBC),  red blood cell count (RBC), hemoglobin  
(HGB), hematocrit (HCT),, platelet count  (UNVPLT),  neutrophils (NEUTP) , lymphocytes (L YMP) . 
E: Additional  liver function  tests (aspartate  transaminase  (AST),  alanine  transaminase  (ALT),  total bilirubin  (TBILI))  measured  every  2 weeks  for the first 
4 cycles  of treatment.  These  labs may be done  locally . 
F: Adequate archival metastatic tissue  can be used lieu of the baseline biopsy if  done when patient had CRPC (within 6 months of treatment start). 
G: Will be performed at baseline, Cycle 2,  and End  of Study . 
H: A  second  optional tumor biopsy will be requested  in patients with confirmed  radiographic  progression  of disease on abiraterone acetate \prednisone 
alone arm . Biopsy will take place prior to starting cabazitaxel  
I: For  Arm 1: On confirmed radiographic progression of disease, the abiraterone acetate will be discontinued and patients will be treated with cabazitaxel 
25mg/m2  IV every 3  weeks  for a maximum  of 9 cycles  at the discretion  of the treating physician . CT scans/MRI and  bone  scans  are required every  3 cycles 
of cabazitaxel treatment beginning on Cycle 4.  End of  Study  scans  can be performed  ± 30 days  from End of  Study Visit.  Patients will continue to have 
procedures  performed as outline in section 6.2 and 6.3. Please see section 6.4  for additional Progression on Arm 1 details . 
J: For Arm 2: Patients  will get a maximum  of 9 cycles  of cabazitaxel  and if the patients  have  not shown  evidence  of confirmed  radiographic  progression  
after 9 cycles of cabazitaxel,  patients will continue on the abiraterone acetate and prednisone  until disease progression or until the  therapy is not 
tolerated . Patients will continue to have procedures  perform as outline in section 6.2 and 6.3  
K: End of  study  visit must  occur within 30  days of  stopping  study  treatments . Patients withdrawn from the study because of AEs will be followed until the 
AE has either resolved or stabilized (minimum of every 4 weeks).  
L: Study treatments must  occur within  7 days  of randomization 
M: Testosterone, androstenedione, DHEAS  
 
 
Treatment/Intervention/Dose -modification  schema  
 
Figure  7. Treatment  schema  
 
 
 
All patients will have a tumor biopsy performed  on an assessable  metastatic tumor  or 
primary  prostate.  Adequate archival  metastatic tissue can be used lieu of the  baseline 
biopsy if done when  patient  had CRPC  (within  6 months  of treatment start).  RB status will  
 
 
 
 
 
 
 
 
 
 
 
 
Arm2:  
 
Cabazitaxel  + 
Abiraterone \Prednisone  Cabazitaxel    
         
Tumor  BiopsyF  X       
Circulating  Tumor  Cells  by EPICG   X  X   X 
Androgen  Panel   X  X   X 
Plasma  for cDNA   X  X   X 
 
        
Abiraterone  /Prednisonel    X -------------------------------- ----- Xl  
Cabazitaxell    X -------------------------  X   
 

MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  22  
  
 
be determined by the  IHC stains (RB positive or negative) at Thomas Jefferson University. 
All patients  will also have  circulating  tumors  cells  collected  as part of the  correlative 
studies.  
 
1. Arm  1: Abiraterone  acetate  1000  mg po daily  + prednisone  5 mg po BID 
On confirmed radiographic progression of disease the abiraterone acetate will be 
discontinued  and patient  will be treated  with cabazitaxel  25 mg/m2 IV every  three  weeks 
for a maximum of  9 cycles  at the  discretion of  the treating  physician. A second tumor  biopsy 
may be performed prior to starting cabazitaxel. Premedications should be given as per 
outlined below.  
2. Arm  2: CabazitaxeI  25 mg/m2 IV+ abiraterone  acetate 1000 mg  po daily+  prednisone 
5 mgpo BID  
Patient will get  a maximum of  9 cycles of  cabazitaxel and if  the patients have not  shown 
evidence of  confirmed radiographic progression after  9 cycles  of cabazitaxel, patients will 
continue on the abiraterone acetate and prednisone until disease progression or until the 
therapy is not tolerated.  
Abiraterone acetate 1000 mg  po daily+  prednisone 5 mg po BID. No food should be  consumed 
for at  least two  hours b efore the  dose of abiraterone acetate is taken and for at  least one hour 
after the dose of abiraterone acetate is taken.  
 
IV cabazitaxel 25 mg/m2 IV every 3 weeks with premedications according to institutional 
standards  
The use of G -CSF support is  allowed after cycle 1 of therapy at the investigators discretion 
according to the ASCO guidelines.  G-CSF may be administered to reduce the risks of 
neutropenia complications associated with cabazitaxel use. Primary prophylaxis with G -CSF 
should be conside red in patients with high -risk clinical features (age > 65 years, poor 
performance status, previous episodes of febrile neutropenia, extensive  prior radiation  ports, 
poor nutritional status, or other serious co -morbidities) that predispose them to increase d 
complications from prolonged neutropenia. Therapeutic use of G -CSF and secondary  
prophylaxis should  be considered  in all patients  considered  to be at increased  risk for 
neutropenia complications.  
6.1 Screening/Pretreatment  Assessment  
Before initiating any  screening  activities, the scope of the  study  should be explained to each 
patient. Patients should be advised of any known risks inherent in the  planned  procedures, 
any alternative  treatment  options,  their  right  to withdraw  from  the study  at any time for 
any reason,  and their  right  to privacy. After  this explanation,  patients  should  be asked  to 
sign and date a Notice of Privacy Practice research authorization/HIPAA  form and an IRB­ 
approved  statement  of informed  consent  that meets  the requirements  of the Code  of 
Federal Regulations  (Federal  Register Vol. 46, No.  17, January 27,  1981, part  50). 
The screening  visit will determine  patient  eligibility  according  to the inclusion  and 
exclusion  criteria  (Sections  3.1 and 3.2).  Patients  will complete  screening/baseline  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  23  
  
 
assessments  prior to treatment start.  The following assessments will be performed at this 
visit.  
Within  28 days  prior  to treatment  start:  
 
• Informed  consent and  research  authorization/  HIPAA  form  
• Demographics,  medical  history,  histologic  and radiologic  confirmation  of disease  
• Discuss concurrent medications (see Appendix B for a listing of medications with the 
potential for drug interactions)  
• Correlative  studies:  
o Tumor biopsy (Note: Adequate  archival  metastatic tissue can be used in lieu of 
the baseline biopsy if done when the patient had CRPC, within 6 months of 
treatment start)  
• Imaging (If imaging is being used to document progression of disease for study 
eligibility, assessments must be performed wi thin 28 days prior to treatment start. Any 
other  assessments  not utilized  for documentation  of disease  progression  but are 
required  for study entry can  be performed  within  42 days  prior to  treatment  start)  
o  Contrast -enhanced CT of the  chest and contrast -enhanced CT of the  abdomen  
and pelvis. For patients unable to receive contrast -enhanced CT of the  chest 
abdomen and pelvis, a chest X -ray and MRI of the abdomen and pelvis will be 
allowed.  
o Radionuclide  bone  scan 
Within  14 days  prior  to treatment  start:  
 
• Physical  exam  including  vital signs,  weight,  height  and EKG  
• Karnofsky  or ECOG  performance  status  (Appendix  A) 
• Halabi  Nomogram  Risk (Appendix  L) 
• Laboratory  studies  
o CBC  
o Serum  Chemistry  
o Liver  Function  Tests  
o PSA 
o Serum Testosterone  
o Serum Triglycerides  
• Correlative  studies  
o Circulating  Tumor  Cells  by EPIC  
o Androgen  Panel  
o Plasma  for cDNA  
Relevant information should be documented. The institutional registration should be 
finalized, and appropriate documents (i.e., signed informed consent, research 
authorization/HIPAA  form, eligibility checklist, and supporting source documentation for 
eligibility questions) emailed to the PCCTC. Information for patients who do not meet  the 
eligibility criteria to participate in this  study (i.e.,  screening failures) should be captured in 
Caisis at the  pretreatment assessment.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  24  
  
 
6.2 Day 1 of Each  Cycle(±  7 days)  
On each  visit,  the following  assessments  will be performed:  
• Physical  examination,  vitals,  weight,  blood pressure  
• Karnofsky  or ECOG  performance  status  (Appendix  A) 
• Discuss  concurrent  medications  
• Toxicity/  Adverse  Event  assessments  
• CBC  (additional  weekly  CBCs  drawn  during  first cycle  of cabazitaxel  treatment)  
• Serum  Chemistry  
•  Liver Function Tests (Additional liver function: aspartate transaminase (AST), alanine 
transaminase  (ALT),  total bilirubin (TBILI) measured every  2 weeks  for the first  4 cycles 
of treatment. These labs may be done locally)  
• PSA 
• Circulating  Tumor  Cells  by EPIC,  Androgen  Panel,  cDNA  (Cycle  2 only)  
 
Note:  
Arm  1 patients are required to receive the above assessments for Cycles  1-3 and every  3 
cycles±  7 days  starting  from Cycle 4 (Cycle 4,  7, 10, etc.).  On confirmed radiographic 
progression of disease on abiraterone acetate, the patients will receive the assessments 
listed in  section 6.2  on Day  1 of each cycle of  cabazitaxel and  will follow  the Arm 2 
treatment schedule from C1D1 including imaging.  
Arm 2 p atients are required to receive the above assessments for Cycles 1 -9. Patients 
continuing abiraterone acetate after  completing  9 cycles of cabazitaxel will receive the 
above assessments every 3 cycles starting with Cycle 10  (Cycle 13,  16, 19, etc.) 
 
 
6.3 Every  3 Cycles  (Cycle  4, 7,10,  ETC.,±  7 days)  
 
• Imaging  
o  Contrast -enhanced CT of the  chest and contrast -enhanced  CT of the  abdomen 
and pelvis. For patients unable to receive contrast -enhanced CT of the  chest 
abdomen  and pelvis,  a chest  X-ray and MRI  of the abdomen  and pelvis  will be 
allowed.  
o Radionuclide  bone  scan 
• Tumor  Measurement  
• Serum  Triglycerides  
 
6.4 Progression  on Arm  1 
On confirmed radiographic  progression of disease, the abiraterone acetate will be 
discontinued.  
Cabazitaxel treatment must be initiated within   28 days  of discontinuing abiraterone 
acetate.  
Patients  will have  a new baseline  CTC,  cDNA,  and androgen panel  drawn  within  14 days  of 
starting therapy with cabazitaxel.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  25  
  
 
 
 
6.5 End of Study  (30 days  of stopping  protocol  study  treatments)  
A patient  may be discontinued  from  study  treatment  at any time  if the patient  or the 
Investigator  feels  that it is not in the patient's  best interest  to continue  on study.  The 
following  is a list of possible reasons  for early  discontinuation  of study  treatment  
• Disease  progression  per protocol  
• Patient  is not compliant  with study  procedures  
• Lost to follow -up 
• Patient  withdrawal  of consent  
• Treatment -limiting  adverse  event  
 
A treatment -limiting  adverse event is any AE related  to protocol therapy experienced 
during the study resulting in treatment termination. Patients  withdrawn  from the  study 
because  of AEs will be followed until  the AE  has either  resolved or  stabilized (minimum of 
every 4 weeks). Reasons  for premature  withdraw al should  be determined  and noted.  
 
The following  study  activities  will occur  at End of Study  Visit:  
• Physical  exam  including  vital signs,  weight,  blood  pressure  
• Karnofsky  or ECOG  performance  status  (Appendix  A) 
• Discuss  concurrent  medications  
• Toxicity/  Adverse  Event  assessments  
• Imaging  (Can  be performed±  30 days from  End of Study  Visit)  
o  Contrast -enhanced  CT of the chest  and contrast -enhanced  CT of the abdomen 
and pelvis. For patients  unable to receive contrast -enhanced CT of the  chest 
abdomen and pelvis, a chest X -ray and MRI of the  abdomen and pelvis will be 
allowed. Radionuclide  bone scan  
• Tumor  Measurement  
• CBC 
• Serum  chemistry  
• Liver  Function  Tests 
• PSA • Serum Testosterone  
• Circulating  Tumor  Cells 
• Androgen  Panel 
• Plasma  for cDNA 
6.6 Correlative/Special  Studies  
Each patient will have the following specimens obtained at the study  site as described 
below:  
a)  A paraffin embedded tumor sample (block or 5 -10 unstained slides; S micron 
thickness) from a new biopsy of a metastatic site of disease or prostate primary 
within 4 weeks prior to treatment start.  Adequate archival  metastatic tissue can be 
used  lieu of the baseline biopsy  if done  when patient had  CRPC (within  6 months  of 
treatment start).  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  26  
  
 
b)  In a patient undergoing a soft  tissue biopsy to determine RB  status, an additional 
tumor  sample will be collected to be placed in media/serum for expla nt culture in 
sites participating in the explant protocol.  
c)  Blood  for circulating  tumor  cells  by EPIC:  screening  (baseline),  Cycle  2, and End of 
Study  - total of 3 tubes (1  Streck  and 2 PAXgene)  
d) Blood  for androgen  panel by  HPLC  (pre-treatment  and End of Study,  1 red top tube).  
e) Plasma collected for circulating DNA ( pre -treatment and End of Study, Streck ™ Cell- 
Free DNA BCT tube (Streck Inc.)  
The rationale, and a brief overview, for collection and handling of these specimens are 
described  below. Further te chnical  details regarding biopsies of metastatic sites, handling 
and shipping  of these  biopsy  specimens  can be found  in the Lab/Correlative  Studies  Manual.  
6.6.1.  Collection  and Handling  of Biopsy  Specimens  
Patients will be scheduled for a CT or  ultrasound -guided biopsy of a bone or soft 
tissue abnormality consistent with prostate metastasis or transrectal ultrasound  
guided biopsy of a recurrent tumor in the prostate. PET or  MRI guided biopsies are 
acceptable. Alternatively,  a standard bone marro w biopsy of the  posterior iliac bone 
may be obtained. The site of biopsy will be determined after review of available 
radiographs, CT, MRI, ultrasound and/or bone scan, and will be selected based 
whatever site is expected to result in the best access, best  yield and is safe for the 
patient.  Verbal and written informed consent will be obtained per institutional 
standards.  While the exact number of  specimens obtained depends on the size of the 
target,  the difficulty of the  procedure, and risk  of complications , the goal is  to obtain 
2-3 samples.  
The soft or bone tissue samples will be sent to pathology for analysis to confirm the 
diagnosis  of prostate cancer  (at the  Institution of participant registration). A portion 
of the  confirmed paraffin tumor  embedded block will be sent to Thomas Jefferson 
University  for RB analysis  as described below  in Section  6.6.5.  Shipping of  specimens 
after collection.  
If patient undergoes a  soft tissue biopsy to determine RB  status, an additional tumor 
sample  will be collected  in media/serum  for explant  culturing in sites  participating 
in the explant protocol.  
All tissue samples will be  labeled with the clinical protocol number, the patient's 
study registration number, and specimen ID.  In addition, a separate informati on 
sheet accompanying each specimen will be filled out (Please see Lab/Correlative 
Studies Manual).  
Following biopsy, samples from metastatic sites or recurrent disease in the prostate 
need  to be shipped  to Thomas  Jefferson  University  per shipping  directions 
described below.  Samples may be shipped Monday through Thursday. Samples will 
not be accepted on the weekends.  
6.6.2.  Circulating  tumor  cells (CTC):  sample  collection  procedure  
Blood will be  collected  at screening (baseline), Cycle 2,  every 3  cycles beginning on 
Cycle  4 and End of Study.  At each of these time  point, blood samples  will be drawn  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  27  
  
 
into one 10-mL evacuated blood  draw  tubes (Cell -Free DNA  BCT  Streck  tube;  EPIC) 
and two  2.5 ml PAXgene tubes.  These blood samples can be maintained at room 
temperature. The Streck tube will be shipped to EPIC SCIENCES for overnight 
delivery. The PAXgene tubes can be shipped overnight at ambient temperatures or 
frozen and batch shipped to Mem orial Sloan Kettering Cancer Center.  See the study­ 
specific laboratory manual for further details on CTC sample collection, processing 
and shipping (Laboratory/Correlatives Studies Manual). These samples will be used 
to give cell count of CTC and the tumo r cells and the DNA \RNA will be isolated to 
perform genomic analysis for RB function.  
6.6.3.  Procedures  for processing  tumor  samples,  plasma  and serum  samples  
 RB IHC from  paraffin  blocks  
Formalin -fixed  paraffin -embedded  tissue  from  400 archived  specimens  with 
prostate cancer will be placed in a tissue microarray (TMA) using the Veridiam ® 
tissue arrayer with Institutional IRB approval.  40 cancer cases will be placed in a 
single TMA block with control cases. Immunohistochemical (IHC) staining with  the 
RB monoclonal antibody from Cell Signaling Technology ® will be applied  [RB 
(4H1) Mouse mAb #9309L]. An automated IHC staining protocol (ultra View DAB 
vl.02.0018)  will be used  on the Ventana  automated  stainer  (Benchmark  XT, 
Ventana  Medical Systems, Inc.,  Tucson, AZ).  The stained slides will be evaluated by 
two pathologists (RD  and RB) without clinical data to  obtain  a consensus result.  The 
IHC stained  TMA  slides  will then be scanned  and analyzed  digitally  using  the Aperio  
® computer assisted image analysis system.  A standardized  nuclear analysis 
protocol  will be used for scoring a minimum  of 1,000 cells. The digital scoring will 
be reported as percentage and absolute number of nuclear staining with nuclear  
scores from 0 to 3+  intensity.  Endothelial nuclear staining will be used as internal 
control. The Aperio  ® results  will be compared  to the pathologists'  consensus 
results and the discrepant cases will be excluded. RB will be consider positive when 
25% or more of the  nuclei h ave a combination of 2+ and 3+ score. Weak positive 
with 10% to 24% of the  cells have a combination of 2+ and 3+ score; and negative 
when less than 10% of the  cells have a combination  of 2+ and 3+ score.  
RB functional  analyses  via custom  array1 
 
cDNA  generated  from  the tumor  biopsy  and collected  CTCs  will be used  to assess 
functional  status  of the RB pathway.  Probeset  intensities  for transcripts  assayed  on 
the RBTARGET will be assessed using robust multichip average (RMA) algorithm in 
Affymetrix  Expression  Console  software.  Additional  analysis  will be performed  on 
the processed dataset using high -level programming languages for statistical 
computing,  includi ng Rand  Matlab.  Twenty  distinct  gene  groups  represented  on the 
RBTARGET array, where genes within each group are highly correlated, will be 
assessed using an Affymetrix U133A Prostate Cancer training dataset.  The 
RBTARGET  expression  profiles  for genes  in each  group  will be averaged  together, 
resulting in twenty independent feature variables.  These twenty feature variables 
will be used  in supervised multivariate analysis  to determine  a linear  equation that 
is best able to classify distinct characteristics o f prostate cancer and inform 
diagnosis/prognosis.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  28  
  
 
Serum  Samples  for Androgen  panel  (testosterone,  androstenedione, DHEAS)  
In an analysis of patients  receiving abiraterone after prior ketoconazole  therapy it 
was observed  that a high  proportion  of patients  had undetectable  androgen  levels 
and that there was an association between lack of response to abiraterone and an 
undetectable level  of DHEAS.(Ryan et al  Proc  ASCO 2011) Further,  in the COU -301 
study patients with above median baseline serum androgens were associated with a 
higher PSA response rate after  adjusting for treatment and other laboratory 
parameters (i.e., LDH, hemoglobin, ALP; all P < .0001).  Thus knowing  the androgen 
levels  may also be a major factor to the  response to abiraterone acetate.  
Serum  for androgen profile  will be collected prior  to the initiation  of treatment  and 
at end of study. Collect 10 mL of whole blood in a serum separator  tube (SST) 
(red/gray  top).  The tube should be  inverted  several  times  to mix clot activator  with 
the blood. Allow the  blood to clot for a minimum of 30 minutes in a vertical position. 
Observe  a dense  clot. Centrifuge  clotted  blood  for 15 minutes  at 1600  x g, 4°C (or  in 
accordance with manufacturer's  instructions).  The serum should be  separated and 
frozen  in cyrotubes  and stored  in -80°C.  The samples  will be shipped  on dry ice and 
shipped  overnight  mail to the Knudsen  lab. Please  note the samples  can be batched 
shipped but do not  ship on Fridays.  
The assay to be used for determining the androgen panel  (testosterone , 
androstenedione,  DHEAS  and other  androgen  derivatives)  will be performed  in the 
laboratory  of Dr. Trevor  Penning  at the University  of Pennsylvania and/or  a CLIA 
certified laboratory  that specializes in  ultrasensitive  endocrine  analyses.  
 Plasma  collected  for circulating  DNA  
 
Plasma collected for circulating DNA_will be collected prior to the initiation  of 
treatment and at End of Study visit. Please see the study -specific  laboratory manual 
for further  details  on plasma  sample  collection,  processing  and shipping 
(Laboratory  /Correlative Studies Manual).  
6.6.5.  Shipping  of specimens  after  collection  
Tumor,  plasma  and blood  (serum)  samples  
All samples  will be shipped  to Thomas  Jefferson  University  at the  following  address:  
Renee de Leeuw 
215-503-8579  
Thomas  Jefferson  University  
233 South  10th  Street, BLSB 1006 
Dr. Karen Knudsen Lab 
Philadelphia, PA 19107  
E-mail:  Karen.Knudsen@jefferson.edu  
Adam .Hawkins@jeffer son.edu  
renee.deleeuw@jefferson.edu  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  29  
  
 
Note:  Tissue  collected  for explant  protocol  at MSKCC  may be shipped  to Dr. Slovin's 
laboratory for processing and analysis.  
 
•  Paraffin  embedded  tumor  samples:  The paraffin  embedded tumor  samples  can be 
shipped  via standard  mail,  at room  temperature.  It is requested  that efforts  be made  to 
ship the tumor  samples within 30  days  of patient  enrollment onto  the trial.  
• Serum and plasma samples  for the androgen panel  and circulating DNA  will be  shipped 
frozen on dry ice  
Shipping must  occur only Monday -Thursday,  and an e-mail or  phone call to 
the contact listed on the laboratory contact sheet, alerting her to the 
shipment, is required.  A copy of the  sample requisition form should also be 
emailed to  the PCCTC  at pcctc@mskcc.org.  
For further details  regarding shipping, please refer to  the 
Laboratory  /Correlative Studies Manual.  
1. PAXgene  tubes  will be shipped  overnight  to: 
MSKCC Laboratory Medicine 
Attn.  CTC  samples  for AA ± Cabazi  
411 E. 67th  Street,  S-359 
New York, NY 10065  
Tel (212)  639-5969  
 
Please note, PAXgene tubes can be  frozen and batch shipped on dry ice  if processed 
per instructions in the  Laboratory/Correlatives Studies Manual. Shipping  
reservations  must  be made to allow delivery within  24 hr  of specimen  collection, 
and prior  to 2:00 PM the  next day. Samples must  not be drawn  or shipped on Friday.  
 
2. EPIC:  Tube  will be shipped  overnight  to: 
 
Epic  Sciences  
Attn.  EPIC  samples  for AA ± Cabazi  
9381  Judicial  Drive,  Suite  200 San Diego,  CA 9221,  USA  
 
Samples should be kept at room temperature at all times.  Shipping reservations 
must be made to allow  delivery within 24  hr of  specimen collection, and prior  to 
2:00 PM the  next day.  
7. THERAPEUTIC  MODALITIES  
7.1 Pharmacokinetics  
7.1.1 Cabazitaxe/23,24  
A population  pharmacokinetic  analysis  was conducted  in 170 patients  with solid 
tumors at doses  ranging from 10  to 30 mg/m2 weekly  or every three weeks.  
Absorption  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  30  
  
 
Based on the  population pharmacokinetic analysis, after an intravenous dose of 
cabazitaxel  25 mg/m2  every  three  weeks,  the mean  Cmax  in patients  with 
metastatic  prostate  cancer  was 226 ng/mL  (CV 107%)  and was reached  at the end 
of the one-hour infusion (Tmax).  The mean  AUC in patients with metastatic prostate 
cancer was 991 ng·h/mL (CV 34%).  
No major deviation from the dose proportionality was observed from 10 to 30 
mg/m2 in patients with advanced solid tumors.  
 Distribution  
The volume of distribution  (Vss) was 4,864 L (2,643 L/m2 for a patient with a 
median BSA of 1.84 m2) at steady state.  
In vitro,  the binding  of cabazitaxel  to human  serum  proteins  was 89 to 92%  and was 
not saturable up to 50,000 ng/mL, which covers the maximum concentration 
observed in clinical trials.  Cabazitaxel is mainly bound to human serum albumin 
(82%)  and lipoproteins (88%  for HDL,  70%  for LDL,  and 56%  for VLDL).  The in 
vitro  blood -to-plasma  concentration  ratio  in human  blood  ranged  from  0.90 to 0.99, 
indicating  that cabazitaxel was  equally  distributed between  blood  and plasma.  
 Metabolism  
Cabazitaxel is  extensively  metabolized in  the liver(> 95%),  mainly  by the CYP3A4/5 
isoenzyme (80% to  90%),  and to  a lesser extent by  CYP2C8.  Cabazitaxel is  the main 
circulating moiety in human plasma. Seven metabolites were detected in plasma 
(including the 3  active metabolites issued from O -demethylation),  with the main one 
accounting  for 5%  of cabazitaxel exposure.  Around 20 metabolites of cabazitaxel are 
excreted into human urine and feces.  
Based on in vitro studies, the potential for cabazitaxel to inhibit drugs that are 
substrates of other CYP isoenzymes  (1A2, -2B6, -2C9, -2C8, -2C19, -2E1, -2D6, and 
3A4/5) is  low. In addition, cabazitaxel did not induce CYP isozymes in  vitro.  
 Elimination  
After a one -hour intravenous infusion [14C] -cabazitaxel 25 mg/m2, approximately 
80% of the  administered dose was elimin ated within 2 weeks.  Cabazitaxel is mainly 
excreted in the feces as numerous metabolites (76% of the  dose); while renal 
excretion of cabazitaxel and metabolites account for 3.7% of the dose (2.3% as 
unchanged drug in urine).  
Based on the population pharmac okinetic analysis, cabazitaxel has a plasma 
clearance of 48.5 L/h (CV 39%; 26.4 L/h/m2 for a patient with a median  BSA of 1.84 
m2) in patients  with metastatic prostate cancer.  Following  a one-hour  intravenous 
infusion, plasma concentrations of cabazitaxel can be described by a three­ 
compartment pharmacokinetic  model with a-, -, and y- half-lives of 4  minutes, 2 
hours, and 95 hours, respectively.  
 Renal  Impairment  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  31  
  
 
Cabazitaxel is minimally excreted via the kidney. No formal  pharmacokinetic trials 
have been conducted with cabazitaxel in patients with renal impairment. The 
population  pharmacokinetic analysis  carried  out in 170  patients  including 14 
patients with moderate renal impairment (30 mL/min:,; CLcr < SO mL/min) and 59 
patients with mild renal impairment (SO mL/min:,; CLcr < 80 mL/min) showed that 
mild to moderate renal impairment did not have meaningful effects on the 
pharmacokinetics of cabazitaxel. No data are available for patients with severe renal 
impairment or end -stage renal disease  
 Hepatic  Impairment  
No formal trials in patients with hepatic impairment have been conducted. As 
cabazitaxel is  extensively  metabolized in  the liver,  hepatic  impairment is  likely  to 
increase the cabazitaxel concentrations.  
 Drug  Interactions  
As cabazitaxel is mainly metabolized by  CYP3A in vitro,  strong CYP3A inducers or 
inhibitors are expected to affect the pharmacokinetics of cabazitaxel. Prednisone or 
prednisolone administered a t 10 mg daily did not affect the pharmacokinetics of 
cabazitaxel.  
Adverse  Events  
The most common (:::: 10%) Grade 1 -4 adverse reactions with cabazitaxel were 
anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue,  nausea, 
vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, 
peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.  
The most common (:::: 5%) Grade 3 -4 adverse reactions in patients who received 
cabazitaxel were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, 
fatigue, and asthenia  
7.1.2 Abiraterone  acetate25 
Following oral administration of abiraterone acetate, the pharmacokinetics of 
abiraterone and abiraterone acetate have been studied in healthy subjects and in 
patients with metastatic CRPC. In vivo, abiraterone acetate is converted to 
abiraterone. In clinical studies, abiraterone acetate plasma concentrations were 
below  detectable  levels  (< 0.2 ng/mL)  in > 99%  of the analyzed  samples.  
Absorption  
Following oral administration of abiraterone acetate to patients with metastatic 
CRPC, the  median time to reach maximum plasma abiraterone concentrations is 2 
hours. Abiraterone accumulation is observed at steady -state, with a  2-fold higher 
exposure (steady -state AUC) compared to a single 1000 mg dose of abiraterone 
acetate.  
At the  dose of 1000 mg daily in patients with metastatic CRPC, steady -state values 
(mean±  SD) of Cmax  were  226 ± 178  ng/mL  and of AUC  were  1173  ± 690 ng.hr/mL.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  32  
  
 
No major deviation from dose proportionality  was observed in the dose range of 
250 mg to 1000 mg.  
Systemic exposure of abiraterone is increased when abiraterone acetate is 
administered with food.  Abiraterone Cmax  and AUC0 -oo were  approximately 7 - and 
5-fold higher, respectively, when abiraterone acetate was administered  with a low­ 
fat meal (7% fat, 300 calories) and approximately 17 - and 10 -fold higher, 
respectively, when abiraterone  acetate was administered  with a  high-fat (57% fat, 
825 calories) meal. Given the normal variation in the content and composition of 
meals, taking abiraterone with meals has the potential to result in increased and  
highly variable exposures. Therefore, no food should be consumed for at l east two 
hours  before the  dose of abiraterone is taken and for at  least one hour after the dose 
of abiraterone is taken. The tablets should  be swallowed  whole with water.  
 Distribution  and Protein  Binding  
Abiraterone is highly bound (>99%) to the human pla sma proteins, albumin and 
alpha -1 acid glycoprotein. The apparent steady -state volume of distribution  (mean± 
SD) is 19,669 ± 13,358 L. In vitro studies show that at clinically relevant 
concentrations, abiraterone acetate and abiraterone are not substrates of P­ 
glycoprotein (P -gp) and that abiraterone acetate is an inhibitor of P -gp. No studies 
have been conducted  with other transporter  proteins.  
 Metabolism  
Following oral administration of 14C -abiraterone acetate as capsules,  abiraterone 
acetate is hydrolyzed to abiraterone (active metabolite). The conversion is likely 
through esterase activity (the esterases have not been identified) and is not CYP 
mediated. The two main circulating metabolites of abiraterone in human plasma are 
abiraterone sulphate (inactive) and N -oxide abiraterone sulphate (inactive), which 
account for about 43% of exposure each. CYP3A4 and SULT2A1 are the enzymes 
involved in  the formation of N -oxide abiraterone sulphate and  SULT2A1  is involved 
in the forma tion of abiraterone sulphate.  
 Excretion  
In patients with metastatic CRPC, the  mean terminal half -life of abiraterone in 
plasma (mean ± SD) is 12 ± 5 hours. Following oral administration of 14C­ 
abiraterone acetate, approximately 88%  of the  radioactive dos e is recovered in feces 
and approximately 5% in urine. The major compounds  present in feces are  
unchanged  abiraterone  acetate  and abiraterone  (approximately  55%  and 22%  of 
the administered dose, respectively).  
 Patients  with Hepatic  Impairment  
The pharmacokinetics  of abiraterone was  examined in  subjects  with baseline mild 
(n = 8) or moderate (n = 8) hepatic impairment (Child -Pugh Class A and B, 
respectively) and in 8 healthy control subjects with normal hepatic function. 
Systemic exposure to abirate rone after a single oral 1000 mg dose given under 
fasting  conditions  increased  approximately  1.1-fold and 3.6-fold in subjects  with 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  33  
  
 
mild and moderate baseline hepatic impairment,  respectively. The mean half -life of 
abiraterone is prolonged to approximately 18 hours in subjects with mild hepatic 
impairment and to approximately 19 hours in subjects with moderate hepatic 
impairment. Abiraterone  has not been studied  in patients  with baseline severe 
hepatic impairment (Child -Pugh Class C)  
 Patients  with Renal  Impairment  
The pharmacokinetics of abiraterone were examined in patients with end -stage 
renal disease (ESRD) on a stable hemodialysis schedule (N=8) and in matched 
control  subjects  with normal  renal  function (N=8).  In the ESRD  cohort  of the trial, a 
single  1000  mg abiraterone acetate  dose  was given  under  fasting  conditions  1 hour 
after dialysis, and samples for pharmacokinetic analysis were collected up to 96 
hours  post dose.  Systemic  exposure  to abiraterone after  a single  oral 1000  mg dose 
did not increase in  subjects with end -stage renal disease on dialysis, compared to 
subjects with normal renal function.  
Phase I  pharmacokinetic (PK) studies showed increased systemic drug exposure at 
higher doses  but antitumor  activity was present at all doses tested. Adrenal 
metabolite analysis showed inhibition of CPYl  7 even at low doses of abiraterone 
acetate  and a compensator y increase  of corticosterone  and deoxycorticosterone. 
Data from dose -finding studies indicated that when  PK, adrenal CYPl  7 inhibition, 
and efficacy signals are  taken into consideration, the 1000 -mg dose offered 
consistent pharmacological effects  without additional side effects. Therefore, the 
1000 -mg dose has been  chosen for further  efficacy  and safety evaluation  in this 
Phase II trial.  
 
 
Adverse  Events  
The most common adverse drug reactions (::::5%) reported in clinical studies were 
joint swelli ng or discomfort, hypokalemia, edema, muscle discomfort, hot flush, 
diarrhea,  urinary  tract infection,  cough,  hypertension,  arrhythmia,  urinary 
frequency, nocturia, dyspepsia, and upper respiratory tract infection.  
The most common adverse drug reactions th at resulted in drug discontinuation 
were aspartate aminotransferase increased, alanine aminotransferase increased, 
urosepsis  and cardiac  failure (each  in <1%  of patients  taking  abiraterone  ). 
Adverse reactions and laboratory abnormalities related to mineralocorticoid effects 
were reported more commonly in patients treated with abiraterone than in patients 
treated  with placebo:  hypokalemia  28% versus  20%, hypertension  9% versus  7% 
and fluid rete ntion (edema) 27% versus 18%, respectively. In patients treated with 
abiraterone, Grades 3 to  4 hypokalemia occurred in 5%  of patients and Grades 3  to 4 
hypertension was reported in 1% of patients.  
7.2 Dosage  Selected,  Preparation,  and Schedule  of Administration  
Cabazitaxel  (Jevtana)  will be administered  at 25 mg/m2 IV every  3 weeks.  The dose  of 
cabazitaxel  will be calculated  as per institutional  guidelines.  Abiraterone  acetate  will be 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  34  
  
 
taken daily at 1000mg PO daily in a  fasting state along with prednisone 5mg PO BID to 
minimize mineralocorticoid side effects. Cabazitaxel will be supplied by Sanofi S.A. but 
distributed  through  the vendor  Biologics. Abiraterone  will be commercially  supplied 
through patient's insurance.  
7.2.1  Supply and Packaging  
 How  Supplied  
Cabazitaxel is  supplied as  a kit containing one  single -use vial of Jevtana (cabazitaxel) 
Injection (clear glass vial with a grey rubber closure, aluminum  cap and light green 
plastic flip -off cap) and one  vial of Diluent  for Jevtana Injection (13% (w/w)  ethanol 
in water for injection) in a clear glass vial with a grey rubber closure, gold -color 
aluminum  cap and colorless plastic flip -off cap. Both items are  in a blister pack in 
one carton.  
Injection 60 mg/1.5 mL (NDC 0024 -5824 -11) is supplied as a kit consisting of the 
following : 
-Jevtana Injection 60 mg/1.5 mL: contains 60 mg cabazitaxel in 1.5 mL polysorbate 
80, 
- Diluent  for Jevtana Injection 60 mg/1.5 mL:  contains  approximately 5.7  mL of 13% 
(w/w) ethanol in water for injection.  
Administration  Precautions  
Jevtana  is a cytotoxic anticancer  drug and caution should  be exercised  when 
handling  and preparing  Jevtana  solutions,  taking into account  the use of 
containment devices, personal protective equipment (e.g., gloves), and preparation 
procedures.  
Instructions  for Preparation  
Do not use PVC infusion containers or polyurethane infusions sets for  preparation 
and administration of Jevtana infusion solution.  
Read  this entire  section carefully  before mixing  and diluting.  Jevtana requires  two 
dilutions prior to administration. Please follow the preparation instructions 
provided below. Note: Both the  Jevtana Injection and the diluent vials contain an 
overfill to  compensate for  liquid loss  during  preparation.  This overfill  ensures  that 
after  dilution  with the entire  contents  of the accompanying  diluent,  there  is an initial 
diluted  solution containing  10 mg/mL  Jevtana.  
The following  two-step dilution  process  must  be carried  out under  aseptic 
conditions to prepare the second (final) infusion solution.  
Set aside  the Jevtana  Injection  and supplied  diluent  vials.  The Jevtana  Injection  is a 
clear  yellow  to brownish -yellow  viscous  solution,  if appropriately  stored.  
• Step  1 - First Dilution  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  35  
  
 
Each vial of Jevtana 60 mg/1.5 mL must first be mixed with the entire contents of 
supplied diluent. Once  reconstituted, the resultant solution contains 10 mg/mL of 
Jevtana.  
When  transferring  the diluent,  direct  the needle  onto  the inside  wall of Jevtana  vial 
and inject  slowly  to limit  foaming.  Remove the syringe  and needle  and gently  mix 
the initial diluted solution by  repeated inversions for at least 45  seconds to assure 
full mixing  of the drug  and diluent.  Do not shake.  
Let the  solution  stand for a few minutes to allow any foam  to dissipate, and check 
that the  solution is homogeneous and contains no visible particulate matter. It is not 
required  that all foam  to dissipate  prior to continuing the  preparation  process.  
The resulting initial diluted Jevtana solution (cabazitaxel 10 mg/mL) requires 
further dilution b efore administration. The second dilution should be done 
immediately (within  30 minutes)  to obtain  the final  infusion  as detailed  in Step 2. 
• Step  2 - Second  (Final)  Dilution  
Withdraw  the recommended  dose  from  the Jevtana  solution  containing  10 mg/mL 
as prepared  in Step 1  using a calibrated syringe and further dilute into a sterile 250 
mL PVC -free container of either 0.9% sodium chloride solution or 5% dextrose 
solution for infusion.  If a dose greater than 65 mg  of Jevtana is required, use  a larg er 
volume of the  infusion vehicle so that a concentration of 0.26 mg/mL Jevtana is not 
exceeded. The  concentration  of the  Jevtana  final  infusion  solution  should  be 
between 0.10 mg/mL and 0.26 mg/mL.  
Jevtana  should  not be mixed  with any other  drugs.  
Remove the syringe and thoroughly mix the final infusion solution by gently 
inverting the bag or bottle.  
Jevtana final infusion solution (in either 0.9% sodium chloride solution or 5% 
dextrose solution) should be used within 8 hours at ambient temperature  (including 
the one-hour  infusion)  or within  a total  of 24 hours  if refrigerated  (including the 
one-hour infusion).  
As the  final infusion solution is supersaturated,  it may crystallize over time. Do not 
use if this occurs and discard.  
Inspect  visually for particulate matter, any crystals and discoloration prior to 
administration. If the  Jevtana first diluted solution or second (final) infusion 
solution is  not clear or  appears to  have precipitation,  it should be  discarded.  
Discard  any unused  portion.  
7.2.2 Administration  
Cabazitaxel  
The final Jevtana infusion solution should be administered intravenously as an 
approximately one -hour infusion at room temperature.  
Use an in-line filter  of 0.22 micrometer  nominal  pore size during  administration.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  36  
  
 
The final Jevtana infusion solution should be used immediately. However, in -use 
storage time can be longer under specific conditions, i.e. 8 hours under ambient 
conditions (including the one -hour infusion) or for  a total of 24 hours if refrigerated 
(including the one -hour infusion).  
Abiraterone  acetate  
Abiraterone acetate 250 mg, immediate release, uncoated tablets are white to off­ 
white, oval -shaped, debossed with AA250 on one side. In addition to 250 mg 
abiraterone acetate , each tablet contains the following compendia! inactive 
ingredients:  lactose  monohydrate,  microcrystalline  cellulose,  croscarmellose 
sodium, povidone, sodium lauryl sulfate, magnesium stearate and colloidal silicon 
dioxide. Abiraterone acetate 250 mg tabl ets are available in high -density  
polyethylene bottles of 120  tablets.  
7.2.3 Storage  requirements  
Cabazitaxel  
Jevtana  Injection  and Diluent  for Jevtana:  
Store  at 25°C  (77°F);  excursions permitted between  15°-30°( (59° -86°F). 
Do not refrigerate.  
Stability  of the First  Diluted  Solution  in the Vial:  First diluted  solution  of Jevtana 
should be used immediately (within 30 minutes). Discard any unused  portion.  
Stability of the Second (Final) Dilution Solution in the Infusion Bag: Fully prepared 
Jevtana infusion solution (in either 0.9% sodium chloride solution or 5% dextrose 
solution) should be used within 8 hours at ambient temperature (including the 
approximately one -hour infusion), or for a total of 24 hours (incl uding the 
approximately one -hour infusion)  under the refrigerated  conditions.  
In addition, chemical and physical stability of the infusion solution has been 
demonstrated for 24 hours under refrigerated conditions. As both the first diluted 
solution  and the second  (final)  infusion  solution  are supersaturated, the solutions 
may crystallize over time.  If crystals and/or particulates  appear, the solutions  must 
not be used and should be discarded.  
Abiraterone  acetate  
Store tablets at 20°C to 25°C  (68°F to 77°F); excursions permitted to 15°C to 30°C 
(59°F to 86°F).  
7.2.4 Special  handling  and disposal  
Cabazitaxel  
Procedures for proper handling and disposal of antineoplastic drugs should be 
followed.  Several  guidelines  on this subject  have  been  published  [see References]. 
Any unused product or waste material should be disposed of in accordance with 
local requirements.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  37  
  
 
If Jevtana Injection, first diluted solution, or second (final) dilution for intravenous 
infusion should come into  contact with the skin, immediately and thoroughly wash 
with soap and water. If Jevtana Injection, first diluted solution, or second (final) 
dilution  for intravenous  infusion  should  come  into contact  with mucosa, 
immediately and thoroughly wash with water.  
References:  
1.  NIOSH Alert: Preventing occupational exposures to antineoplastic and other 
hazardous drugs in healthcare settings. 2004. U.S.  Department of Health and 
Human Services, Public Health Service, Centers for Disease Control and 
Prevention, National  Institute for Occupational Safety and Health, DHHS 
(NIOSH) Publication No. 2004 -165.  
2. OSHA  Technical  Manual,  TED  1-0.15A,  Section VI:  Chapter 2.  Controlling 
Occupational  Exposure to Hazardous Drugs. OSHA, 1999. 
http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html  
3. American Society of Health -System  Pharmacists. (2006) ASHP Guidelines  on 
Handling  Hazardous  Drugs.  Am J Health -Syst Pharm  2006;  63:1172 -1193.  
4.  Polovich, M., White, J. M., & Kelleher, L.O. (eds.) 2005. Chemotherapy and 
biotherapy  guidelines  and recommendations  for practice  (2nd.  ed.) 
Pittsburgh, PA: Oncology Nursing Society.  
Abiraterone  acetate  
Based on its mechanism of action, abiraterone may harm a developing fetus. 
Therefore, women who are pregnant or women who may be pregnant should not 
handle abiraterone without protection, e .g., gloves.  
7.2.5  Handling  and Dispensing  
Abiraterone and prednisone will be commercially supplied and dispensed. Patients 
will be provided  with a diary in  which  to record  their  intake  of study  drug 
(Appendix G).  
Cabazitaxel will be supplied  by Sanofi -Aventis and dispensed at the institution of 
registration. Study site personnel will record cabazitaxel administered  during this  
trial on a drug dispensation log as per institutional policy at each site. The drug 
dispensation log will contain the  following information:  
o patient  study  identification  number  
o date(s)  of cabazitaxel  administered  
o quantities  of cabazitaxel  administered  
7.3 Dose  Modifications  and Dose  Delay  
At each study visit for the duration of their participation in the  study, patients will be 
evaluated for  adverse  events  (AEs,  all grades),  serious  adverse  events  (SAEs),  and AEs that 
require study drug interruption or discontinuation.  
If a patient has a greater than 2 week delay in receiving cabazitaxel  due to a drug -related 
AE, then cabazitaxel should  be discontinued. If  a patient has a  greater than 2  week  delay  in 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  38  
  
 
receiving abiraterone due to a drug -related AE, then abiraterone should be discontinued.  A 
delay greater  than 2 weeks and no more than 6 weeks of cabazitaxel  due to an event that is 
not related to protocol therapy or after a patient receives limited field palliative radiation is 
acceptable.  A delay greater than  2 weeks and no more than 6  weeks of abiraterone  due to an 
event that is not related to protocol therapy or after a patient receives  palliative radiation is 
acceptable.  
Arm 2 patients who either requi re that the study drug to be discontinued because of a 
treatment -related  AE (as described  below)  or have  a treatment  interruption  of greater  than 
2 weeks for abiraterone acetate or 2 weeks for cabazitaxel  due to a treatment -related AE, at 
the investigator's discretion,  may continue  on the other  agent  alone  until  progression  as 
long as they have completed 2 cycles of combination therapy. Further  details on the dose 
modifications for study drugs are in section 7.3.  
Patients  discontinued  from  the treatment  phase  of the study for  any reason  will be 
evaluated approximately 30  days after the last dose of the  study drug. Any  patient 
hospitalized during  the study will be evaluated and treated as per supervising physician and 
appropriate communication  reports to the PCCTC will be completed in a timely manner as 
per the FDA guidance for Industry.  
General  Rules  
Every effort will be made to administer the full dose regimen to maximize dose -intensity.  If 
possible, toxicities should be managed symptomatically. If toxicity occurs, the appropriate 
treatment will be used to ameliorate signs and symptoms  including antie metics for nausea 
and vomiting, anti -diarrheals for diarrhea, and antipyretics, and/or antihistamines for drug 
fever.  
Toxicity  will be assessed  using  the most  recent  NCICTCAE,  v4.0.  
7.3.1 Dose  modification  for abiraterone  acetate  
 
 
 
 
 
 
 
 
 
 
I 
 
 
For any grade  2 or greater toxicity thought to be related  to the  abiraterone  acetate, 
the dose will be held until grade   1 toxicity. The dose of may be restarted at one 
lower dose level.  The dose of abiraterone acetate will not be re -escalated  once a 
dose reduction  has occurred. Patients  may have a maximum  of two dose reductions 
of abiraterone  acetate.  If patient  after  two dose  reductions  still has intolerance  to 
the abiraterone acetate then the drug should be discontinued. The patient may 
continue  on with the cabazitaxel  or prednisone  without  the abirateron e acetate  at 
the investigators discretion.  
Asymptomatic  laboratory  abnormalities  would  not be considered  a SAE  unless  the 
investigator  believes  it may potentially  impact  the participant's  safety  or unless  it is 
specifically addressed separately in the  protocol (e.g., hypokalemia and liver test 
abnormalities).   Dose  Level    Abiraterone  acetate  I Prednisone  
 o   1000  mg daily  I 5 mg twice  daily  
 -1   750 mg daily  I I 5 mg twice  daily  
-2 500 mg daily  5 mg twice  daily  
 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(B)  
Page  39  
  
 
Due to the known side effect of hypokalemia, oral replacement of potassium is  to be 
started with Grade 1 hypokalemia.  With Grade 3 or 4 hypokalemia,  abiraterone 
acetate is  to be held until it resolves to  :s; Grade  1 and IV  potassium  replacement is  to 
be given with appropriate monitoring. The dose of abiraterone acetate should be 
restarted at one reduced dose level as described above.  
If Grade 2 or hig her liver function test abnormalities (AST, ALT or bilirubin) 
develop, the liver function tests  should be  followed at least  weekly until they resolve 
to :5 Grade 1. If Grade 3 liver test abnormalities (AST, ALT or  bilirubin)  develop, 
abiraterone  acetate  and any other  hepatotoxic  drugs  should  be held until  they 
resolve to :s; Grade 1. In the specific case of Grade 3 AST, ALT or bilirubin 
abnormalities, a mandatory dose reduction of abiraterone acetate to 500 mg daily 
must be u ndertaken, with every 2 week assessments of the  liver function tests for at 
least  3 months. If Grade 4  liver test  abnormalities (AST,  ALT  or bilirubin) occur,  the 
drug should be permanently discontinued. The PCCTC should also be notified with 
any Grade 3 o r 4 liver function test abnormality. If a dose reduction of abiraterone 
acetate below 500 mg daily is required, the abiraterone acetate will be discontinued 
and the cabazitaxel  may be continued at the discretion of the  investigator.  
Prednisone is  included  in this regimen primarily as a  safety medication to reduce 
the potential incidence of mineralocorticoid excess from abiraterone acetate. For 
this reason, the prednisone cannot be dose reduced or held without holding the 
abiraterone acetate.  If Grade 3  or Grade 4  toxicity develops which is known to  be 
related  to prednisone  (e.g.  hyperglycemia)  and this is believed  to potentially  impact 
the safety of participation, prednisone must be tapered down and abiraterone 
acetate  should  be held until  the AE resolves  to :5 Grade  1. 
7.3.2 Dose  modification  for cabazitaxel  
 
Dose  Level  Cabazitaxel  
0 25 mg/m2 
-1 20 mg/m2 
-2 15 mg/m2 
Patients may have a maximum of two dose reductions and the minimal dose of 
cabazitaxel  to be administered  is 15  mg/m2 every  3 weeks.  The dose, which  has 
been reduced for  toxicity,  must not be re -escalated. Only two dose reductions will be 
allowed per patient. If more than two dose reductions are required per the 
modifications below, the patient should be removed from the study.  
Patients may  use G-CSF support  at the discretion of  the treating  physician after  cycle 
1 of therapy. If a patient has a greater than 2 weeks delay in receiving cabazitaxel, 
then cabazitaxel should be discontinued. If the  cabazitaxel is discontinued for 
intolerable tox icities,  patients may continue on the abiraterone acetate and  
prednisone alone until POD or intolerable AEs from the abiraterone acetate.  
 Hematologic  toxicity  
The dose cabazitaxel depending on the treatment arm will be modified in  case of 
hematological toxicity. Dose modifications are summarized in Table  1. 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(B)  
Page  40  
  
 
Table  1. Dose  modifications  for hematological  toxicity  
Toxicity  Grade 2 Grade  3 Grade  4 
 
No dose  reduction  if isolated  and duration  :,;7 days. 
 
 
 
 
Neutropenia  If not recovered on 
D21, delay** next 
infusion until  
recovery to Grade ::;1 
(neutrophil ;,;1.5 x 
109/L). 
- 1st episode: No  dose 
reduction required.  
- znd episode;  reduce 
by 1 dose level  If duration more than 7  days or not recovered on D21 
Delay** next  infusion until ANC  ;,;1.5  x 109 /Land:  
- 1st episode: reduce the dose  1 dose level and in  addition 
administer prophylactic G -CSF treatment in subsequent 
cycles if patient did not received G -CSF.  
- 2nd episode  or 1st episode  despite prophylactic G -CSF: 
Reduce dose by 1 dose level.  
- 3rd episode  or 2nd episode  despite prophylactic G -CSF: 
Withdraw from study treatment  
 
 
 
Febrile  neutropenia  
or neutropenic  Not applicable  
infection  
 
Delay**  next infusion 
until recovery to 
Grade ::; 1  (platelets  
Thrombocytopenia  ;,;75 x 109/L). 
No dose  reduction 
required.  Delay** next  infusion  until recovery and ANC ;,;1.5 x  109 /L 
and: 
- 1st episode: reduce the dose  1 dose level and administer 
prophylactic G -CSF treatment in subsequent cycles . 
- 2nd episode:  Withdraw  from  study  treatment  
Delay**  infusion  until platelets  ;,;75 x 109 /L 
If Grade 3 without delay, no dose reduction  required . 
If Grade  4 with or  without  delay,  or Grade 3  with delay  
- 1st episode:  Reduce  dose  by 1 dose  level.  
- 2nd episode:  Withdraw  from  study  treatment  in case of 
recurrence  
 
 
** maximum  of 2 weeks  delay,  otherwise  the patient  will discontinue  cabazitaxel  
 
Blood counts will be performed in  case of fever or infection. Blood count  should be 
monitored  weekly  for the first cycle  to determine  if G-CSF or dosage  modification is 
needed. Study treatment should  not be given to patients  with neutrophil  counts  
<1,500  cells/mm3• 
Deaths due to sepsis following severe neutropenia have been reported in patients 
treated with cabazitaxel. Neutropenic complications should be managed promptly 
with antibiotic  support  and use  of G-CSF should be  considered according  to ASCO 
guidelines. Infe ctions concomitant with Grade 3 -4 neutropenia should be reported 
with the term "neutropenic infection" in the  eCRF.  
No dose  modification  will be  made  for anemia; patients  will be supported 
appropriately  by the  treating  physician  (the investigator  can refer  to ASCO 
guidelines).  
 
 
 
Allergy  (Anaphylactic and  Hypersensitivity  reactions))  
Hypersensitivity reactions that occur despite premedication are very likely to occur  
within  a few minutes  of start of the first or of the second  infusion  of cabazitaxel.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(B)  
Page  41  
  
 
Therefore,  during  the 1st and the 2nd infusions,  careful  evaluation  of general  sense 
of well being  and of blood pressure  and heart  rate will be performed  for at least  the 
first 10 minutes, so that immediate intervention would occur in response to 
symptoms of an untoward reaction.  
Facilities and equipment for res uscitation along with the medications (i.e., 
antihistamine,  corticosteroids,  aminophylline,  and epinephrine)  must  be 
immediately available. If a reaction occurs, the specific treatment that can be 
medically indicated for a given symptom  (e.g., epinephrine in case of anaphylactic 
shock, aminophylline  in case of bronchospasm, etc)) will be instituted. In  addition, it 
is recommended  to take the measures listed below:  
 
Mild: localized  cutaneous 
reaction, such as:  
pruritus, flushing, rash.  o Consider  decreasing  the rate of infusion  until  recovery  of 
symptoms,  stay at bedside  
o Complete  cabazitaxel  infusion  at the  initial  planned  rate.  
Moderate:  Generalized 
pruritus, more severe  
flushing or rash, mild 
dyspnea, hypotension 
with systolic  B8.P.  >80 
mmHg  o Stop  cabazitaxel  infusion  
o  Give  IV diphenhydramine  50 mg and/or  !VIV  dexamethasone 
10mg  
o  Once all signs and/or symptoms of hypersensitivity reaction 
disappear, cabazitaxel may be  reinfused within 24 hours from 
the interruption, if medically appropriate, and whenever 
possible.  
o Re-administer  premedication  regimen  as described  in Section  
7.2 when  cabazitaxel  is reinfused  more  than 3 hours after  the 
interruption  
o Administer  cabazitaxel  over 2  hours  for all subsequent  
infusions  
Severe:bronchospasm, 
generalized urticaria, 
hypotension with systolic 
B8.P .:::;80 mmHg,  
angioedema.  o Stop  cabazitaxel  infusion  
o Give IV  diphenhydramine  50 mg and/or IV  dexamethasone 10 
mg 
o Add epinephrine** or bronchodilators  and/or IV plasma 
expanders if indicated  
o  Once all signs and/or symptoms of hypersensitivity reaction 
disappear, cabazitaxel may be  reinfused within 24  hours from 
the interruption, if medically appropriate, and whenever 
possible  
o Re-administer  premedication  regimen  as described  in Section  
7.2 when  cabazitaxel is  reinfused  more  than 3 hours  after  the 
interruption  
o Administer cabazitaxel over 2 hours for  all subsequent 
infusions  
o If a severe  reaction  recurs,  patient  will go off protocol  therapy  
Anaphylaxis  (Grade  4 
reaction)  Withdraw  treatment  
 Nausea/Vomiting  
A prophylactic  anti-emetic  treatment should  be given to  the patients  in all cycles. 
The use of metoclopramide is recommended. More aggressive  anti-emetic 
prophylaxis (i.e., ondansetron, etc.) should be given to the patient who has 
experienced Grade ::::3 nausea/vomiting in a preceding cycle. If despite the 
appropriate  medication,  Grade  ::::3 nausea/vomiting  still occur,  reduce  the dose  of 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(B)  
Page  42  
  
 
cabazitaxel.  If despite  dose  reduction  and prophylaxis,  nausea/vomiting  still occur 
at Grade  3, the patient  should  be withdrawn from  treatment  with cabazitaxel.  
Stomatitis  
If Grade  3 stomatitis  occurs,  cabazitaxel  should  be withheld  until  resolution  to Grade  
:51. Treatment may then be resumed, but the dose of cabazitaxel should be reduced 
by 1  dose level for all subsequent  doses. In case of  Grade 4 stomatitis,  the patient 
will be withdrawn from treatment with cabazitaxel.  
 Diarrhea  
No prophylactic treatment for diarrhea is recommended in Cycle 1. However, 
following  the first episode  of diarrhea,  the patient  should  be treated  with 
rehydration or antidiarrheal medications as needed. In case of Grade  3 diarrhea or 
persisting diarrhea despite appropriate medication, fluid and electrolytes  
replacement,  delay treatment until improvement or resolution, then reduce the dose 
by 1  dose level. If despite  dose  reduction,  diarrhea  still occurs at  Grade  3, the 
patient will be withdrawn from treatment with cabazitaxel.  
 Renal  function  
No dose adjustment is necessary in patients with renal impairment not requiring 
hemodialysis. Patients presen ting with end -stage disease (creatinine clearance 
CLrn<15mL/min/1.73m 2), should be monitored carefully during treatment [see 
Clinical Pharmacology (12.3].  
 Hematuria  
An imbalance in the incidence of hematuria was observed in the Phase  III study in 
second line mCRPC (EFC6193). More hematuria was reported in cabazitaxel arm 
versus  mitoxantrone  arm (62 patients/16.7%  versus  14 patients/3.8%).  In 
cabazitaxel arm, no clear possible explanation such as local 
infection/obstruction/progression , or anticoagulation/aspirin therapy, or 
thrombocytopenia was found  for 21 patients. In addition, in prior studies conducted  
in metastatic breast cancer, a total of 6 patients (2 in the ARD6191 and 4 in the 
TCD6945) experienced cystitis without local infec tion including 5 hemorrhagic 
cystitis (3 cystitis were documented with biopsy).  
Therefore, in case of hematuria with no clear possible explanation every efforts 
should be undertaken to document the cause (e.g., urine cultures, urinary tract 
ultrasound, and  if no cause identified cystoscopy with or without biopsy).  
 Peripheral  neuropathy  
Dose  modification  should  be performed  as follows:  
o Grade  :51: No change  
o Grade  2: Retreat  with reduced  dose  (reduce  by 1 dose  level)  
o Grade  3: Patient  will be withdrawn  from  treatment  with cabazitaxel  
 Liver  toxicity  
Cabazitaxel is extensively metabolized  in the  liver. Patients with mild hepatic 
impairment (total bilirubin > 1 to :5 1.5 x ULN or  AST > 1.5 x ULN) should have 
cabazitaxel  dose reduced  to 20mg/m2. Patients  with moderate  hepatic  impairment  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(B)  
Page  43  
  
 
(total bilirubin > 1.5 to :,; 3.0 ULN and AST = any) should have cabazitaxel dose 
reduced to 15 mg/m2. Administration of  cabazitaxel to patients with mild and 
moderate hepatic impairment should be undertaken with caution and close  
monitoring of safety [see Clinical Pharmacology (12.3) ). Cabazitaxel is 
contraindicated in patients with severe hepatic impairment  (total bilirub in > 3 x 
ULN).  
Other  Toxic  Effects  
For <! Grade 3 toxicities except fatigue, local reaction, fluid retention, anemia and 
other toxicities that merely are  uncomfortable but do not cause serious morbidity to 
patients, chemotherapy should be held for a maximu m of 2 weeks from the planned 
date of reinfusion until resolution to :,; Grade 1, then reinstituted, if medically 
appropriate. A dose reduction  of subsequent doses (1 dose level) will be left to the 
investigator's  judgment.  These  patients  will be withdrawn  from  study  treatment  if 
>2 dose reductions are needed. Any measures such as frozen gloves or socks or 
scalp cooling cap to prevent nail toxici ty or alopecia are left to the investigator's 
judgment.  
7.4 Removing  Patients  from  the Protocol  
In the absence of  treatment delays because  of AEs,  treatment will  continue until one  of the 
following criteria applies:  
• patient  decides  to withdraw  from  the study  
• disease  progression  
• study  closure  
• symptomatic  disease  progression  at any time 
• objective  clinical  disease  progression  
• intercurrent  illness  that prevents  further  administration  of treatment  
• unacceptable  AE(s) that may or may not be directly related to treatment but  that, in the 
judgment of the  treating physician,  makes it dangerous for the  patient to be retreated  
• general or specific changes in the  patient's condition that render the patient unacceptable 
for further treatment, in the  judgment of the  investigator  
Because  an excessive  rate of withdrawals  can render  the study  not interpretable, 
unnecessary withdrawal  of patients should  be avoided. When a patient discontinues 
treatment early, the investigator should make every effort to contact the patient and to 
perform a final evaluation. The reason(s) for withdrawal should be recorded.  
7.5 Concomitant  Medications and  Supportive  Care  
Because of the  potential for drug -drug interaction, the concurrent use of all other drugs, 
over-the-counter  medications, and alternative therapies must be documented on the CRF. 
The principal investigator should be alerted if the  patient is taking any agent found in 
Appendix B (a listing of medications with the potential for drug -drug interactions).  
7.5.1 CYP450  system  
Abiraterone causes  inhibition of P450  CYPs 2C19,  2D6 and 1A2.  So any medications 
known to be metabolized by the P 450 system should be used with  caution. 
Abiraterone is thought to be a weak inhibitor of these enzymes.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(B)  
Page  44  
  
 
7.5.2 Anticoagulants  
Anticoagulants  should be  held prior to biopsy to  obtain tumor to check the  RB status 
of the  tumor.  
7.5.3 Supportive  care 
Use of growth factors will be should  be utilized  as needed to reduce complications 
from cabazitaxel after first cycle of therapy  as per ASCO guidelines.  
8. SAFETY  EVALUATION  AND  REPORTING  
8.1 Definitions  
An adverse event (AE) is  any untoward medical occurrence in  a research patient during  a 
clinical study or within 30 days post -treatment, regardless of causality. This includes 
adverse clinical or laboratory findings, any  adverse drug reaction (ADR), an illness with 
onset during th e study, or an exacerbation of preexisting illness or condition.  
8.2 Recording  and Grading  
8.2.1 Recording  
All observed or volunteered AEs, regardless of treatment group, severity, suspected causal 
relationship, expectedness, or seriousness will be recorded. The NCI  CTCAE v4.0 will be 
used for recording and grading AEs.  
Follow -up of AEs should continue until the event and any sequela resolve or stabilize at a 
level acceptable  to the  investigator  and the  lead site/sponsor  or medical  monitor.  
A clinically significant change in a physical examination finding or an abnormal test result 
(i.e., laboratory, x -ray, EKG) should be recorded as  an AE, if it: 
o is associated  with accompanying  symptoms  
o requires  additional  diagnostic  testing  or medical  or surgical  intervention  
o leads  to a change  in study dosing  or discontinuation  from  the study  
o requires  additional  concomitant  drug  treatment  or other  therapy,  or 
o is considered  clinically  significant  by the investigator  or sponsor.  
MSK  IRB# : 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  45  
  
 
An abnormal test result that is subsequently determined to be in error does not require 
recording as  an AE, even if it  originally met  one or more of the  above criteria.  
8.2.2 Grading  severity  
All AEs will be  graded for  intensity on a  scale of 0  to 5. Severity  grades  will be  recorded and 
based on the CTCAE version 4.0.  
8.2.3 Attributing  causality  
After grading for severity, the investigator must evaluate all clinical AEs and abnormal 
laboratory values for possible  causal  relationship  to the study drugs. Causality attribution 
will be classified  as either "related" or "non -related".  
Abnormal laboratory values of clinical significance that  were present at baseline and 
did not change in severity or frequency during experimental therapy or  intervention 
and those that can obviously be attributed to underlying disease will be recorded as 
unrelated and will not be considered when evaluating the maximum tolerated dose 
(MTD).  
8.3 Unexpected  Adverse  Events  
An unexpected AE is  any event not  associated  by nature or  intensity  with the investigational 
agent under  study.  The Comprehensive Adverse Event  and Potential Risks (CAEPR) list 
provides a  single, complete list  of reported  and potential  AEs associated  with an agent using 
a uniform presentation of eve nts by body system. In addition to the comprehensive list, a 
subset, the Agent  Specific  Adverse Event List (ASAEL), contains events that  are considered 
expected  for expedited  reporting  purposes  only.  A listing of  expected  and unexpected  
events for the agent(s)  under investigation for cabazitaxel and abiraterone acetate in this 
study may be found in Appendix E.  
8.4 Serious  Adverse  Events  and Serious  Adverse  Drug  Reactions  
Serious  adverse  event  (SAE) : any untoward  medical  occurrence  that at any dose:  
• Results  in death,  
•  Is life threatening, (Note: the  term "life -threatening" refers to an event/reaction in which 
the patient was at risk of death at the time of the  event/reaction;  it does not refer to an 
event/  reaction which  hypothetically might have caused  death if it  were more severe),  
• Requires  inpatient  hospitalization  or results  in prolongation  of existing  hospitalization,  
• Results  in persistent  or significant  disability/incapacity,  
• Is a congenital  anomaly/birth  defect,  or 
•  Is a medically  important  event  or reaction.  Medical  and scientific  judgment  should  be 
exercised in  deciding  whether  other  situations  should be  considered serious,  such  as 
important  medical events  that might not  be immediately life -threatening  or result  in 
death  or hospitalization,  but might  jeopardize  the patient  or might  require  intervention 
to prevent  one of the other  outcomes  listed  in the definition  above.  
Related  Adverse  Event,  i.e. Adverse  Drug  Reaction  (ADR) : There  is a reasonable  possibility 
according to the  sponsor that the product may have caused  the event.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(B)  
Page  46  
  
 
Unexpected Adverse Drug Reaction : An adverse reaction, the nature or severity of which is 
not consistent with the applicable product information  (e.g., Investigator's Brochure for an 
unapproved  investigational  product  or package  insert/summary of  product  characteristics 
for an approved product). An expected ADR with a fatal outcome should be considered 
unexpected  unless the local/regional product labeling specifically states that  the ADR might 
be associated with a fatal outcome.  
All SAEs that occur any  time a patient is on study (i.e., as soon as  the informed  consent has 
been signed) or within 30 days of the  last dose of cabazitaxel or abiraterone acetate must be 
recorded, regardless  of the  suspected  relationship  to the drugs. Any SAE occurring more 
than 30 days after the last dose of the  study drugs  must be  recorded  if a causal  relationship 
to them is suspected.  
8.4.1 Progression  of malignancy  
Progression of  a patient's malignancy  should not  be considered an  AE, unless  in the 
investigator's opinion, study treatment resulted in an exacerbation of the  patient's 
condition. If disease  progression  results in death or hospitalization while on study 
or within 30 days of the  last dose, progressive disease will be considered an  SAE.  
8.4.2 Life-threatening  events  
A life-threatening event  is any AE that places  the patient  at immediate  risk of death 
from the reaction  as it occurs.  It is not a reaction that,  had it occurred  in a more 
severe form, might have caused death.  
8.4.3 Hospitalization  or prolongation  of hospitalization  
Hospitalization encompasses any inpatient admission (greater than 24 hours) 
resulting from a precipitating, treatment -emergent AE. For chronic or long -term 
patients,  inpatient  admission  also includes  transfer  within  the hospital  to an acute 
or intensive  care inpatient  unit. Hospitalizations  for administrative  reasons  or a 
non-worsening preexisting condition should not be  considered AEs (e.g.,  admission 
for workup of a persistent pretreatment laboratory abnormality, yearly physical 
exam, protocol -specified admission, elective surgery). Preplanned treatments or 
surgical procedures should be noted in the baseline documentation.  Hospitalization 
because of an unplanned event will be deemed an SAE.  
Prolongation  of hospitalization  is any extension of an inpatient hospitalization 
beyond  the stay anticipated  or required for the  original  reason for admission.  
8.4.4 Significant  disability  
Disability is  a substantial disruption of the  patient's ability to  conduct normal life 
functions.  
8.4.5 Congenital  anomaly  
If the female partner of a male patient becomes pregnant during the course of the 
study, the treating physician  must be notified immediately. All confirmed 
pregnancies must be immediately reported to the lead investigator and sponsor and 
recorded in the  conso rtium database.  All pregnancies will be followed until 
resolution (i.e., voluntary or spontaneous termination  or birth) and assessed for 
congenital anomalies and birth defects.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(B)  
Page  47  
  
 
8.4.6 Medically significant  event  
An event  that is not fatal or  life-threatening  and that  does not necessitate 
hospitalization  may be considered  serious  if, in the opinion  of the investigator,  it 
jeopardizes  the patient's  status  and might  lead to medical  or surgical  intervention  to 
prevent any of  the above outcomes. Such  medically  significant  events could  include 
allergic  bronchospasm  requiring  intensive  treatment  in the emergency  room  or at 
home,  blood dyscrasias  that do not result  in inpatient  hospitalization,  vasculitis, 
"generalized  edema",  or the development of  drug  dependency  or abuse.  
8.5 Reporting  Serious  Adverse  Events  
8.5.1 Reporting  serious  adverse  events  
All SAEs,  events  determined to  be medically  significant by  the treating  Investigator, 
and unknown reactions or unexpected events should be reported to the lead 
site/sponsor and the PCCTC within 24  hours of knowledge of the  event using  the 
contact  information  below.  The PCCTC  will provide  an initial  notification  of SAEs  to 
Sano fi within 1 business day  of PCCTC awareness or identification  of the  event.  
The initial  report  for each  SAE  or death  should  include  the following  information:  
o protocol#  and title 
o study  identification  number,  sex, age 
o date the event  occurred  
o description  of the SAE 
o causal  relationship  to the study  drug  
The PCCTC  SAE  Report  Form  (Appendix  J) will be used  for reporting  each  SAE  and 
should be  submitted to the PCCTC within 3  calendar days oflearning of the  event. 
When a life -threatening event or death is unforeseen and indicates participants or 
others  are at increased risk  of harm, participating sites  should notify  PCCTC as  soon 
as possible but within 24 hours of the  time the participating site becomes aware of 
the event.  Severity, causality, action taken, concomitant medications, outcome, etc 
should be reported to the PCCTC as soon as possible.  
 
Follow -up of adverse events should continue until the event  and any  seque la resolve 
or stabilize at a level acceptable to the investigator.  
 
The PCCTC will  facilitate all  SAE reporting  to the MSKCC IRB/PB  and Sanofi within 5 
calendar days. PCCTC is responsible for informing all participating sites about all 
unexpected SAEs that  are either possibly, probably, or definitely related to the study 
intervention within 15 days of receiving the stamped SAE report from the MSK 
IRB/PB.  PCCTC is  responsible for  informing  all participating  sites within 24  hours  or 
on the  next business  day about a life -threatening event or death  that is unforeseen 
and indicates  participants or others are at increased  risk of harm.  
 
SAE  contact  information for  the PCCTC,  lead site/sponsor  is listed  below: 
Lead Site Study Pl:  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  48  
  
 
Susan  Slovin,  MD, PhD 
Memorial  Sloan  Kettering  Cancer  Center 
Genitourinary Oncology Service  
1275 York Avenue 
New  York,  NY 10065 
slovins@mskcc.org  
 
 
PCCTC:  
Prostate  Cancer  Clinical  Trials  Consortium 
Phone: 646 -888-0434/646 -422-4383  
Email:   PCCTC@mskcc.org  
 
Sanofi  Pharmacovigilance  Contact:  
Fax: 908-547-8000  
E-mail:  CL-CPV -Receipt@sanofi.com  
8.6 Safety  Reports  
The PCCTC  will distribute  outside  safety  reports  to the  participating  sites immediately 
upon  receipt.  Participating  sites are responsible  for submitting  safety  reports  to their  local 
IRB/PB  as per their local  IRB guidelines.  All local IRB approvals/acknowledgments  of safety 
reports must be sent to the PCCTC upon receipt.  
 
8.7 Unanticipated  Problems  
Unanticipated  problems involving risks to participants or others (UPs) are  defined as  any 
incident, experience or outcome that meets all of the  following criteria:  
•  Unanticipated  (in terms  of nature,  severity,  or frequency)  given (a)  the research 
procedures  that are described  in the protocol -related  documents,  such as the IRB­ 
approved research protocol  and informed consent  document; and (b)  the 
characteristics  of the  subject population being  studied;  and 
•  Related or possibly related to participating in the research (possibly related means 
there is a reasonable probability that the  incident, experience or outcome may have 
been caused by procedures involved in the research); and 
• Suggests that the research  place participants  or others at a greater risk of harm 
(including  physical,  psychological,  economic,  or social harm) than  was previously 
known or recognized.  
Participating sites are responsible for reporting all UPs to PCCTC as  soon as possible but 
within  3 calendar days  oflearning of the  event. UPs that are SAEs should be reported to 
PCCTC via  SAE Report form  as per Appendix D.  All other UPs  should be reporte d to PCCTC 
in a memo signed by the site PI.  
PCCTC is responsible for submitting UPs to the  MSK IRB/PB according to institutional 
guidelines. In addition,  PCCTC  is responsible  for notifying participating sites of all non -SAE 
UPs that may affect the sites.  
MSK  IRB# : 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 49  
  
 
 
9. CRITERIA  FOR  OUTCOME  ASSESSMENT  /THERAPEUTIC  RESPONSE  
9.1 Outcome  Assessment  
All baseline evaluations will be performed as closely  as possible to the beginning of 
treatment. For subsequent evaluations, the method of assessment and techniques will be 
the same as those used at baseline.  
9.1.1 Primary  Objective  
9.1.1.1  To determine the radiographic progression free survival (rPFS) in patients 
treated with abiraterone acetate \prednisone with and without cabazitaxel  in 
patients with chemotherapy nai:ve CRPC.  
9.1.1.2  Secondary  Objectives  
9.1.1.2.1  To determine  PSA  progression  free survival (PSA  PFS)  in patients 
treated with abiraterone acetate \prednisone with and without  
cabazitaxel in patients with chemotherapy nai:ve CRPC  
9.1.1.2.2  To determine the proportion of patients with measurable disease 
regression based on the RECIST treated with abiraterone acetate with  
and without cabazitaxel in patients with chemotherapy nai:ve CRPC.  
9.1.1.2.3  To determine  the overall  toxicity  and survival  for patients  treated  with 
abiraterone acetate with  and without cabazitaxel in patients with 
chemotherapy nai:ve CRPC.  
9.1.1.2.4  To determine the proportion of patients that have an objective response 
using  the RECIST  and post-therapy PSA  decline using  a waterfall plot  in 
patients that are treated with cabazitaxel after progression on the 
abiraterone/predni sone alone arm.  
9.2 Therapeutic  Response  
Response and progression will be evaluated in this study using a combination of the 
international criteria proposed by the Response Evaluation Criteria in Solid Tumors 
(RECIST) Committee (Table  4) and the guidelines for prostate cancer endpoints developed 
by the Prostate Cancer Clinical  Trials  Working  Group (PCWG2,  Table  5).26 
Patients will need to be reevaluated for response every cycle according to the guidelines 
below.  
9.2.1 PSA 
Perform  PSA testing  at a minimum of  1-week intervals with the threshold PSA  level 
at 2.0 ng/mL.  To report PSA -based outcomes, PCWG2 recommends that  the percent 
of change in PSA from baseline to 12 weeks (or earlier for those who discontinue 
therapy)  and the maximu m decline  in PSA that occurs  at any point  after treatment 
be reported  for each  patient  using a waterfall  plot. Because  the rate of  rise has 
shown prognostic  significance, estimate  a pretreatment PSA  doubling  time (PSA -DT) 
if at least  3 values  are available,  but do not delay  either  treatment  or enrollment  
MSK  IRB# : 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 50  
  
 
onto a trial simply  to estimate PSA -DT. Because  declines  in serum PSA,  if they occur, 
may not do so for several weeks, PSA measurements obtained during the first 12 
weeks should not be used as the sole criterion for clinical decision making.zs  
9.2.2 Measurable  disease  
According to  RECIST, measurable disease is defined as at least  1 lesion>  20 mm in 
its longest  diameter  as measured  with conventional  techniques  (i.e., CT  [nonspiral 
or non-helical],  MRI,  physical  exam)  or> 10 mm as measured  with spiral  CT scan.  All 
tumor measurements will be taken using a ruler or calipers and recorded in 
millimeters (or decimal fractions of centimeters).  
9.2.3 Non-measurable  disease  
Following RECIST, all  other lesions (or sites of disease) will be  considered  non­ 
measurable disease. This includes small lesions (longest diameter< 20 mm with 
conventional techniques or<  10 mm using  spiral  CT scan)  and any of the following:  
o bone  lesions  
o ascites  
o pleural  or pericardia!  effusion  
o lymphangitis  cutis  or pulmonitis  
o abdominal  masses  that are not confirmed  and followed  by imaging  techniques  
o cystic  lesions  
o lesions occurring within a previously irradiated area unless they are 
documented  as new lesions since the completion  of radiation therapy  
Note: If only a single, asymptomatic bone lesion is present at baseline, and 
will be irradiated, the metastatic nature of this  lesion must be  confirmed by 
x-ray, CT, or MRI.  
9.2.4 Target  (nodal  and visceral)  lesions  
Following RECIST, progression in a nodal or visceral si te (i.e., liver and lung) is 
sufficient to document disease progression. The presence or absence of nodal and 
visceral  disease before and after treatment should  be recorded  separately.  
All measurable lesions (up to a maximum of 5 lesions  per organ and 10 lesions in 
total)  will be identified  as target lesions to  be measured  and recorded  at baseline. 
The target  lesions  should  be representative of  all involved  organs. Target  lesions 
will be  selected on the basis of  size (i.e.,  the largest  area) and  suitability for  accurate, 
repeated measurements (either by imaging techniques or clinically). The sum of the 
longest diameter (LD) of all target lesions will be calculated and reported as the 
baseline sum LD. The baseline sum LD will be used as a r eference by which to 
characterize the objective tumor response.  
Because small lymph nodes are difficult to measure accurately and may not be 
malignant,  the greatest  diameter  of a lymph  node must measure at least 2 cm  by 
spiral CT to be considered a target lesion.zs  
9.2.5 Bone  lesions  
MSK  IRB# : 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 51  
  
 
When the  bone  scan is  the sole indicator of progression,  disease progression in bone 
is defined  as 2 or more  new lesions seen on  bone scan compared  with a  prior scan 
for used tri al entry.zs  
In situations  where  scan findings  suggest  a flare  reaction  or where  new lesion(s) 
may represent  trauma,  confirm  these results with other imaging modalities  (e.g., 
MRI or fine -cut CT). If many new areas of uptake are observed,  confirmation is 
generally not necessary.  
9.2.6 Non-target  lesions  
All other lesions (or sites of disease) will be identified as nontarget lesions and 
recorded  at baseline.  Nontarget  lesions  will include  measurable  lesions  that exceed 
the maximum number per  organ (5)  or total of all involved organs (10),  as well as 
nonmeasurable lesions.  The presence or  absence of these  lesions will be recorded 
on the CRF  and should  be evaluated  at the same  assessment  time points  as all target 
lesions.  
9.2.7 New lesions  
The appearance of up to 10 new measurable lesions should be recorded. Each new 
lesion should be reassessed using the same imaging modality at each time point. If 
measurable, the LD of each new lesion should be recorded in the CRF and the sum 
LD of new and old lesions should be calculated.  See Table 4  for a description of the 
determination  of progression based on the presence of new lesions.  
Note: The appearance of a new lesion does not by itself satisfy the criteria for 
confirmed progressive disease. Rather , the tumor burden imposed by the new 
lesions must be evaluated within the context of the total tumor burden (i.e., 
preexisting plus new lesions). Confirming progression in target lesions, non­ 
target  (i.e., other  than bone)  lesions,  and bone  lesions  requi res 2 assessment 
time points. The  first must  occur  at Week  9 (or later)  and the second  occurring 
at least 6  weeks  after  the first.  Progression  declared  at the first time point 
remains unconfirmed  unless assessments at the second time point demonstrate 
continuing   or  worsening   progression,   as  described   in  Section   9.4. 
9.3 Response  Criteria  for Control/Relieve/Eliminate  Endpoints  
9.3.1.  Measurable  soft-tissue  lesions  
When  evaluating  soft-tissue  lesions,  the definitions  in Table  2 apply.  
Table  2. REC/ST  response  criteria  for target  (soft-tissue)  lesions  
Response  
Complete response  (CR) 
Partial response (PR) 
Progressive  disease  (PD)  
 
Stable  disease  (SD)  Evaluation  of Soft-Tissue  Lesions  
the disappearance of  clinical and radiological evidence of  all target 
lesions and normalization of tumor marker levels  
a decrease from baseline<'=  30% in the sum of  the LD of  all target 
lesions  
an increase <'= 20%  in the sum of the LD of all target  lesions  based 
on the smallest sum LD since treatment started or the appearance 
of one or more new lesions or the appearance of new lesions  
neither  sufficient  shrinkage  to qualify  for PR nor sufficient  increase  
 
 
MSK  IRB# : 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 52  
  
 
to qualify  for PD based  on the smallest  sum LD recorded  since 
treatment started  
 
Abbreviations:  LD, longest  diameter.  
 
 
In some  circumstances,  it may be difficult  to distinguish  residual  disease  from 
normal  tissue.  When  the evaluation  of complete  response  depends  on this 
determination,  it is recommended  that the residual  lesion  be investigated  (e.g.,  fine 
needle  aspirate  or biopsy) before  confirming  the complete response  status.  
Changes in nodal and visceral sites should be recorded and reported separately, and 
lymph nodes in the pelvis must measure at least 2 cm in greatest diameter to be 
considered target lesions. Complete elimination  of disease at a particular site  should 
be recorded separately. Any favorable change should be confirmed using a second 
follow -up scan.  
9.3.2  PSA 
As long as patient safety  is the primary  concern,  in the absence of other  indicators of 
disease progression,  therapy should  not be discontinued solel y on the  basis of a  rise 
in PSA.  
For each patient, use  a waterfall plot  to report the  percent  change in PSA  from 
baseline to 12 weeks (or earlier for those who discontinue therapy) and the 
maximum decline in PSA that occurs at any point after treatment.  
9.3.3  Bone  
Record  post-treatment  changes as either "no new lesions" or "new  lesions" as 
indicated on the forms in appendix K.  
In the  absence of clearly worsening soft -tissue (nodal and visceral) disease or 
disease -related symptoms, progression at the first scheduled assessment should be 
confirmed  on a second scan  performed  6 or more weeks later. In the  rare case 
where visible lesions disappear, this too should be confirmed.  
9.3.4  Non-target  lesions  
When assessing  non-target  lesions,  the definitions  in Table  3 will apply.  
Table  3. RECIST  response  criteria  for non-target  lesions  
Response  
Complete  response  (CR)  
 
Incomplete response/ 
stable disease (SD)  
Progressive  disease  (PD) Evaluation  of Non-target  Lesions  
the disappearance of  all non -target lesions and normalization of 
tumor marker levels  
the persistence of one or more non -target lesions and/or 
maintenance of tumor marker levels above the normal limits  
the appearance of one or more new lesions and/or unequivocal 
progression of existing non -target lesions  
 
 
 
A clear progression of non -target lesions only is exceptional. In  such circumstances, 
the progression status,  as assigned by  the investigator,  may be reviewed by  a PCCTC 
panel.  
MSK  IRB# : 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 53  
  
 
9.3.5 Evaluating  best overall  response  
The best overall response is  the best  response recorded from  the start  of treatment 
until  either  disease progression or  recurrence.  The investigator's  determination of 
best overall response  will be based  both  on response  criteria  and on confirmation 
criteria.  To be assigned  a status  of partial response  or complete response,  changes  in 
tumor measurements must be  confirmed by  repeat  assessment performed  
4-6 weeks  after  the criteria  for response  are first met. To confirm  stable  disease, 
follow -up measurements  must  meet SD  criteria  at a minimum  interval  of 4 weeks 
after  SD was first documented.  Table  4 can be used  as an assessment tool.  
Table  4. Assessing  Overall  Response  
Target  Lesions  Non target  Lesions  New  Lesions  Overall  Response  
CR CR No CR 
CR Incomplete  response/SD  No PR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
Abbreviations:  CR, complete  response;  PD, progressive  disease;  PR, partial  response;  SD, stable  disease.  
 
 
Patients with global deterioration  of health status who require treatment to be 
discontinued without objective evidence of disease progression should be classified 
as having symptomatic  deterioration. Every effort should  be made to  document 
their objective  progression, even after discontinu ing treatment.  
Patients who do not have tumor response assessment due to rapid progression or 
toxicity will be  considered non -responders,  will be  included in the denominator for 
the response rate, and will be classified into one  of the  categories listed below:  
o death  attributed  to disease  progression  
o early  discontinuation  attributed  to disease  progression  
o death  attributed  to drug  toxicity  
o early  discontinuation  attributed  to drug  toxicity  
Note: If a patient receives subsequent therapy before tumor progression is 
documented, the reason for changing therapy must be reported. Reasons include 
clinical progression, drug toxicity, or secondary therapy f or maintaining tumor 
response  
9.4 Confirmatory  Measures/Duration  of Response  
9.4.1 Confirming  time-to-event  outcomes  
Any post -treatment  change in disease status, be it favorable or unfavorable should 
be confirmed using a second assessment.  
MSK  IRB# : 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 54  
  
 
9.4.2 Duration  of overall  response  
Duration of overall response is measured from the time when partial response or 
complete  response  is first  noted  until  the date when  recurrent  or progressive 
disease is objectively documented. Duration of overall complete response is 
measured  from  the time the criteria  for complete  response  are first met  until the 
first date that  recurrent  disease  is objectively  documented.  Duration  of stable 
disease is measured from the start of treatment until the  criteria for progression are 
met. 
9.4.3 Radiographic  Progression -free survival  
Radiographic  progression -free survival  (rPFS)  is a composite  endpoint defined  as 
the time from  treatment  start to disease  progression  in bone  or soft-tissue,  or 
death, whichever occurs first. All assessments of disease should be c ollected at the 
same  time interval  (e.g.,  bone  scan,  CT scan,  and PSA).  In addition  to PSA,  confirm 
post-treatment changes  in measurable  target lesions,  radionuclide  bone scans, and 
symptoms.  
MSK  IRB# : 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 55  
  
 
Table  5. Prostate  Cancer  Clinical  Trials  Working  Group  Outcome  Measures26 
 
PSA Variable  Control/Relieve/Eliminate  Endpoints 
Record the  percent  change  from  baseline 
(rise or fall) at 12 weeks  and, separately, 
the maximal change (rise  or fall) at any 
time using a waterfall plot  Prevent/Delay Endpoints 
Decline from baseline: record time from 
start of therapy  to first PSA  increase  that is 
~25% and ~2 ng/mL above the nadir, and 
which is  confirmed by  a second value 3 or 
more weeks later (i .e., a confirmed rising 
trend)t  
Recording  the duration  of PSA  decline  of 
little  value  
No decline  from  baseline:  PSA progression  
~25%  and ~2 ng/mL  after  12 weeks  
Soft-tissue  lesions  
 
 
 
 
 
 
 
 
 
 
Bone  Use RECIST  with caveats:  
Only report changes in  lymph nodes that 
were ~  2 cm in diameter at baseline  
Record  changes  in nodal  and visceral  soft 
tissue sites separately  
Record complete  elimination of  disease  at 
any site separately  
Confirm  favorable  change  with second 
scan 
Record changes  using  waterfall  plot 
Record  outcome  as either  new lesions  or 
no new lesions  
First  scheduled  reassessment:  
No new lesions:  continue  therapy  
New  lesions: perform a  confirmatory  scan 
6 or more weeks later  
Confirmatory  scan:  
No new lesions: continue therapy 
Additional new lesions: progression 
Subsequent scheduled reassessments: 
No new lesions: continue  
New  lesions:  progression  Use RECIST criteria for progression, with 
additional requirement that progression at 
first assessme nt be confirmed by a second 
scan 6 or more weeks later  
Note that for some treatments, a lesion may  
increase in size before it decreases  
 
 
 
 
 
The appearance of~ 2 new  lesions, and,  for 
the first reassessment only, a confirmatory 
scan performed 6 or more weeks later that 
shows at least 2 or  more additional new 
lesions  
The date of progression is  the date  of the 
first scan that shows the change  
Symptoms  Consider  independently  of other  outcome  measures  
Document  pain and analgesia at entry with a  lead-in period and measure repeatedly at 3 - 
to 4-week intervals  
Perform  serial  assessments of  global  changes  in HRQOL,  urinary  or bowel  compromise, 
pain management, additional anticancer therapy  
Ignore  early  changes  (~12 weeks)  in pain or HRQOL  in absence  of compelling  evidence  of 
disease progression  
Confirm  response  or progression  of pain or HRQOL  endpoints  ~3 weeks  later 
 
 
Abbreviations : PSA, prostate -specific  antigen; HRQOL, health -related  quality  of life.tParticularly  important  when  anticipated effect  on PSA  is 
delayed or for biologic therapies . 
MSK  IRB# : 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 56  
  
 
 
10. DATA REPORTING  AND  REGULATORY  REQUIREMENTS  
10.1  Data  Collection  and Management  
Data  collected  during  this study  will be entered  into a secure  database.  
10.1.1  Electronic  case report  forms  (eCRFs)  
The participating sites will enter data remotely into electronic Case Report Forms 
(eCRFs)  using  the internet  based  PCCTC  Caisis  Electronic  Data  Capture  (EDC) 
system.  Completion  guidelines  will be created  by the PCCTC  for the collection  of all 
study  data.  Access  and training  for PCCTC Caisis EDC  will be made  available  to 
participating sites upon local regulatory approval.  The participating site PI is 
responsible for ensuring eCRFs are  completed accurately and in a timely manner.  
10.1.2  Source  documents  
Source documentation  refers to original records of observations, clinical findings 
and evaluations that are  subsequently  recorded as data.  Source documentation will 
be made available to support the subject's research record. Source documentation 
must include a minimum of two identifiers to  allow  for data verification. MSK will 
maintain  the confidentiality of any subject -identifiable information  it may 
encounter.  
10.1.3  Record  retention  
The investigator  will maintain adequate and accurate records to enable the conduct 
of the  study to be fully documented and the study data to be subsequently verified. 
The investigator will ensure that  all regulatory documents and participating site IRB 
correspondences are maintained in an onsite regulatory binder. After study closure, 
the investigator will maintain all source documents and study -related documents.. 
Records are  to be retained and securel y stored until the later of:  (a) two (2) years 
following  the date a New Drug  Application  is approved for  the Study  Drug  that is the 
subject of the  Clinical Trial; or (b) two (2) years after the Investigational New Drug 
Application  for such Study Drug is te rminated  or withdrawn,  or such longer  period 
of time as may be required by Participant policies, applicable laws, rules or 
regulations.  
10.1.4  Source Documentation Submission for  Registration at Participating Sites 
Participating sites should email any  source documentation that corresponds to data 
entered at registration to  the PCCTC at   PCCTC@mskcc.org  within 24  hours (see 
Section 4.2.1).  
10.1.5  Data  Submission  Timelines  
All study  data should be  transmitted to  the PCCTC  within  14 days  of visit except  for 
SAE submission (see  section 8.5) as described in the Data Management Plan.  
10.1.6  Data  Review  and Queries  
The PCCTC  will review  data and source  documentation as  it is submitted.  Data  will 
be monitored and source verified as necessary and discrepancies will be sent as 
queries  to the participating  sites.  In addition, the PCCTC will review data  for logic,  
MSK  IRB# : 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 57  
  
 
consistency,  and obvious  anom alies.  Queries  will be sent by the PCCTC  to 
participating sites as needed.  
Participating  sites should  respond  to data queries  within  14 days  ofreceipt.  
10.2 Study  Monitoring  and Quality  Assurance  
10.2.1  Data  and Safety  Monitoring  
The Data  and Safety  Monitoring  Plans  (DSMP) at  Memorial  Sloan  Kettering  Cancer 
Center were approved by the  National Cancer Institute in September 2001.  The 
plans  address  the new policies set forth by  the NCI in  the document entitled  "Policy 
of the National Cancer Institute  for Data  and Safety Monitoring  of Clinical Trials" 
which can be found at:  http://www.cancer.gov/clinicaltrials/conducting/dsm­  
guidelines/pagel . The DSMPs  at MSKCC  were  established and  are monitored by  the 
Office of  Clinical  Research.  The MSKCC DSMPs  can be found  on the MSKCC Intranet 
at: 
http://inside2/  clinresearch/Documents/MSKCC%2 0Data%20and%2  0Safety%2  0M 
onitoring%20Plans.pdf.  
 
There  are several  different  mechanisms  by which  clinical  trials  are monitored  for 
data, safety,  and quality. There  are institutional  processes  in place  for quality 
assurance  (e.g.,  protocol  monito ring, compliance and data verification  audits, 
therapeutic  response,  and staff education  on clinical  research  quality  assurance)  
and departmental  procedures  for quality  control,  plus there  are two institutional 
committees  that are  responsible  for monitoring  the activities  of our clinical  trials 
programs.  There are  several  committees:  Data  and Safety  Monitoring  Committee 
(DSMC) for Phase I and II clinical trials, and the Data and Safety Monitoring Board 
(DSMB) for Phase III clinical trials, report to the MSKCC Research Council and 
Institutional  Review  Board.  As a moderate  risk trial,  this study will  be monitored  by 
DSMC twice per year.  
Since therapeutic efficacy is a stated primary objective, all sites participant's 
responses are subject to review by MSKCC's Therapeutic Response Review 
Committee (TRRC).  Radiology and  additional  lab reports will need  to be obtained  
from  the participating  sites for MSKCC  TRRC  review  and confirmation  of response 
assessment. These materials must be  sent to MSKCC promptly upon request.  
10.2.2  Data  Monitoring  and Quality  Assurance  
In addition to review by DSMC, the  PCCTC will conduct regularly scheduled 
monitoring visits.  
Registration  reports  will be generated  by the  PCCTC  to monitor subject accruals  and 
the completeness of  registration data.  Routine  data quality  reports  will be generated 
to assess  missing  data and inconsistencies.  Accrual rates  and the extent  and 
accuracy  of evaluations  and follow -up will be monitored  periodically  throughout  the 
study  period,  and potential problems  will be brought  to the attention of  the 
Principal Investigator for  discussion and  action.  
MSK  IRB# : 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 58  
  
 
Each  site participating  in the accrual  of participants to  this protocol  will be 
monitored  at a minimum  of 10%  of all subjects,  but at least  2 from  each site, will  be 
100% source  data verified  by the  PCCTC.  Monitoring  will occur once shortly after 
initiation of  subject recruitment at  a site, annually  during  the study  (or more 
frequently  if indicated),  and at the end or closeout  of the trial,  for protocol  and 
regulatory  compliance,  data verification  and source  documentation.  Monitoring 
visits  may be accomplished  in one of two ways:  (1) sending  source  documents  and 
research  records  for selected  patients  from  participating  sites  to the PCCTC  for 
audit,  or (2) on-site monitoring of  selected patient records  at participating  sites.  
The monitoring  visit will include  a review  of source  documentation  to evaluate 
compliance for:  
 
1.  Regulatory  /IRB compliance (review of current protocol and  amendments, 
Informed consent documents and procedures, annual continuing review reports, 
AEs/SAEs)  
2. Protocol  defined  treatment  compliance  
3. Subject  records  
•  Each  subject  is audited to reviewed to determine that  there is  a signed and 
dated consent form  
• Adherence  to eligibility  criteria  
• Baseline,  on study  and follow -up protocol  testing  
• eCRF  completion  
 
Monitoring  visit findings  will be reviewed  and disseminated  to the site Pis and staff.  
In addition, each participating site accruing participants to this protocol will be 
audited by MSKCC for protocol and regulatory compliance, data verification and 
source documentation. Audits of selected participant records may be conducted on­ 
site or rem otely.  
Audits will be  conducted annually at minimum, and more often if  significant and/or 
repeated findings are  identified  during monitoring visits.  The number of 
participants audited will be determined by the outcome of monitoring visits and 
complexity of  the protocol.  
Each  audit  will be summarized  and a final report  will be sent to the  PI at the audited 
participating  site within  30 days  of the audit.  The report  will include  a summary  of 
findings,  participant -specific  case review,  recommendations  on any performance 
and/or  shortcomings and request  for corrective action,  when necessary.  When 
corrective  action  is required,  the participating  site must  reply  within  45 days  of 
receipt  of the audit report  with their  corrective action plan.  
 
11. STATISTICAL  CONSIDERATIONS  
11.1 Endpoints  
The primary endpoint is radiographic progression -free survival (rPFS) defined as the time 
from randomization to minimum of radiographic  progression  or death, whichever occurs 
first.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  59  
  
 
Secondary endpoints include post -therapy changes in PSA, objective response rate (ORR)  
per RECIST  criteria,  PSA  progression -free survival (PSA  PFS),  and toxicity.  
11.2 Sample  Size 
This is a randomized phase II trial in which 80 patients  will be randomized with equal 
probability  to one of two possible  treatment  regimens:  abiraterone  acetate \prednisone 
(AA) or AA plus cabazitaxel (AA+C). The randomization will be stratified by Halabi 
nomogram7 based on low (defined as ( 166.6 points in the  nomogram) or high risk (>166.6 
total points).  
Based  on Ryan  et al. the median  time to radiographic  progression  free survival  (rPFS)  is 
16.5 months.  This trial is non -comparative.  Forty (40) patients will be enrolled in each arm. 
With an accrual rate of  40 patients/arm over 24 -month accrual period,  and assuming that 
rPFS follows an exponential distribution, based on 5,000  simulations the average width of a 
two-sided 95% confidence i nterval for the median rPFS is  16. 
In addition,  this trial will  estimate  the rPFS in  patients  who are  RB negative  and treated 
with either AA or AA+C. It is expected that 60% (48) patients will be RB negative and 40% 
(32 patients) will be RB positive.  The radiographic PFS distribution by RB status and 
treatment arm will not be estimated with high precision. Nevertheless, the data from this 
study  will be valuable for testing feasibility as well as  providing  pilot data for use in 
planning a larger randomized  phase II/III trial.  
Dr. Susan  Halabi  from Duke University will perform statistical  analysis  of this trial.  Data  will 
be de -identified from all sites prior to sending to Dr. Halabi for analysis.  
11.3 Toxicity  Monitoring  
While the combination of AA + C has been safely administered in patients that had prior 
Docetaxel therapy, it is expected that this will also be well  tolerated in the pre­ 
chemotherapy population. However since it has not been used in the pre -chemotherapy 
population, close toxicity monitoring will occur. An unacceptable  toxicity will be defined as 
death or grade 4 febrile neutropenia that is treatment related (probably or definitely 
related to treatment). If at any time during the accrual the observed proportion of 
unacceptable  toxicity  exceeds  15% by  at least  one standard  error  accrual  to the trial will be 
immediately suspended and the trial re -evaluated.  
11.4 Data  Analysis  
The trial is non -comparative and the analysis will be performed  within each arm. The 
Kaplan -Meier  product -limit estimator will be used to estimate rPFS, overall survival, and 
PFS distributi ons. In addition,  the proportion  of patients who are  RB positive  or RB 
negative with exact 95% confidence interval (CI) based on the binomial distribution will be 
computed. RB status will be performed at centralized laboratory at Thomas Jefferson 
Universit y and RB immunohistochemistry status \genomic profile will be performed as 
previously described by Sharma et al.1  
The rPFS distribution will be  estimated in  subgroups of patients who are RB positive or RB 
negative treated with either AA or AA+C. The rPFS di stribution within each arm and RB 
status will  not be  estimated  with high precision.  Nevertheless,  the data from  this study will  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page  60  
  
 
be valuable for testing feasibility as well as providing pilot data for use in planning a larger 
phase 11 \III trial.  
Furthermore, post therapy changes in PSA (50%) and response rates using the RECIST 
criteria (complete+ partial) with exact 95% Cls based on  the binomial distribution will be 
computed. Exploratory analysis will be performed to correlate the RB status with PFS and 
other clinical outcomes.  
12. REGULATORY  AND  PROTECTION  OF HUMAN  SUBJECTS  
12.1 Roles  and Responsibilities  
12.1.1  lead Site/Sponsor Principal  Investigator  
The Sponsor Principal Investigator at the lead  site is responsible for performing the 
following tasks:  
•  Responsibility  for the overall conduct of  the study  at all participating sites and for 
monitoring the progress of the  study  
• Reviewing  and ensuring  reporting  of Serious Adverse  Events  (SAEs)  
• Reviewing  data from  all participating  sites 
12.1.2  PCCTC  
The PCCTC  is responsible  for performing  the following  tasks:  
•  Ensuring that IRB approval has been obtained at each participating site prior to  the 
first patient registration at that site, and maintaining copies of IRB approvals and 
required regulatory documents from each site.  
• Managing  subject  registration  
• Developing  and maintaining  Clinical  Data  Management  documents  and procedures  
• CRF  development,  setup  of study  database,  and subsequent  design  changes  
• Participating  in review  of content  of the CRF  against  the protocol  requirements  
• EDC  system  administration  (user/site  accounts  setup,  maintenance  and revocation)  
• Data  review,  cleaning,  query  management  and resolution  
•  Establishing  procedures  for documentation, reporting  and submitting  of AE's  and 
SAE's to the  PCCTC.  
• Reviewing  Serious  Adverse  Events  (SAEs)  
• Training  participating  sites on EDC  
• Collecting  and compiling  data from each  participating site 
• Data  reviewing  from all  participating  sites 
•  Facilitating audits by  securing  selected source documents and research records 
from  participating sites for audit, or by auditing at  participating sites.  
 
12.1.3  Participating  Sites 
Participating  sites are responsible  for performing  the following  tasks:  
•  Following  the protocol  as written,  the guidelines  of Good  Clinical  Practice  (GCP),  and 
applicable Standard Operating Procedures (SOPs).Registering all patients with the 
PCCTC by  submitting the eligibility  checklist,  supporting source documentation,  and 
signed informed consent promptly  
•  Providing sufficient experienced  clinical and administrative staff and adequate 
facilities and equipment to conduct  a collaborative trial according to the  protocol  
•  Maintaining regulatory binders on  site and providing  copies of all required 
documents to the PCCTC  
• Collecting  and submitting  data according to  the schedule  specified  by the protocol  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page  61  
  
 
• Responding  to queries  in a timely  manner  
12.2 Ethical  Considerations  
This study will be  conducted in  compliance with the  protocol, GCP guidelines established by the 
International Conference on Harmonisation,  and the ethical standards set forth in the Declaration 
of Helsinki 2004 (available at: www.laakariliitto.fi /e/ethics /helsinki.html).  
12.3 Regulatory  Documentation  
Prior  to implementing  this protocol at  MSKCC, the  protocol, informed consent form,  HIPAA 
authorization and any other information pertaining to participants must be approved by the 
MSKCC Institutional Review Board/Privacy Board (IRB/PB). There will be one protocol 
document and each participating site will utilize that document.  
 
The following  documents must  be provided to  the PCCTC before the participating site  can be 
initiated and begin enrolling participants:  
• Participating  Site IRB approval(s) for  the protocol,  appendices,  informed consent  form 
and HIPAA authorization  
• Participating  Site IRB approved  informed  consent  form  and HIPAA  authorization  
• Participating  Site IRB membership list 
• Participating  Site IRB's  Federal  Wide  Assurance  number  and OHRP  Registration  number  
• Curriculum  vitae  and medical  licenses  for each investigator  and consenting professional  
• Curriculum  vitae  for each lab director  
•  Consenting Professionals Lists (consenting professionals at each participating site 
that may obtain informed consent and care for the participants according to good 
clinical practice and protocol guidelines)  
•  Documentation  of Human  Subject  Research  Certification  training  for investigators and 
key staff members at the participating site  
• Documentation  of Good Clinical Practice (GCP)  training  for the Pl and  co-Pl at the 
participating site  
• Participating  site laboratory  certifications  and normals  
 
Upon receipt of the required documents, the PCCTC will submit a  participating site activation 
request to  MSKCC. Once  approved, MSKCC will  formally  contact the  PCCTC and  grant  the site 
permission to proceed with enrollment.  
12.4 Protocol  Amendments  
Before starting  the study,  the protocol must be  approved  by each institution's IRB  or Independent 
Ethics Committee (IEC). Each change to  the protocol document must be  organized and 
documented  by the  PCCTC, reviewed and approved by Sanofi and approved by the MSKCC 
IRB/PB. Protocol amendments that  affect  MSKCC only  (e.g. change in  MSKCC Co -Investigator, 
MSKCC  translation, etc.)  do not require IRB  review at  the participating site(s). All other protocol 
amendments will be immediately distributed to  each participating site upon receipt of MSKCC 
IRB/PB approval.  
Each participating site must obtain approval for all non expedited amendments from their IRB 
within 90 calendar days  of MSKCC IRB/PB  approval. If the amendment is the result of a safety 
issue or makes eligibility criteria more restrictive, sites will not be permitted to continuing 
enrolling  new participants  until the participating  site IRB approval  of the revised  protocol  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page  62  
  
 
document  is granted  and submitted  to the PCCTC,  who  will in turn submit  the approval 
documentation to MSKCC.  
The following  documents  must  be provided to  the PCCTC for  each  amendment within the  stated 
timelines:  
• Participating  Site IRB approval  
• Participating  Site IRB approved  informed  consent  form  and HIPAA  authorization  
 
The PCCTC  is responsible for  submitting  all participating site local  IRB approvals and/or 
acknowledgments to MSKCC upon receipt.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  63  
  
 
12.5 Additional  IRB Correspondences  
 
Continuing  Review  Approval  
The Continuing Review Approval letter from the  participating site's IRB and the most  
current approved version of the  informed consent form should be submitted  to PCCTC 
within  7 days of expiration.  Failure to submit the  re-approval  in the  stated  timeline will 
result in  suspension of new participant enrollment.  The PCCTC is responsible for  submitting 
all participating site  local IRB approvals and/or acknowledgments  to MSKCC upon receipt.  
 
 Deviations  
A protocol deviation  on this study  is defined as  any incident involving non -adherence  to an 
IRB approved protocol. Deviations typically do not have a significant effect on the  rights, 
safety, or welfare of research  participants  or on the  integrity of the  resultant data.  
Deviations that represent unanticipated  problems involving risks to participants  or others, 
or serious adverse events should be reported according to sections 8.5.1  and 8.7 of the 
protocol.  
Deviations that do not adversely affect the  rights and/or welfare of the  participant or the 
scientific validity  of the study  and are related to pro tocol scheduling  changes outside  of the 
allowed window due  to a holiday (e.g., New Year's, Thanksgiving, etc.) and/or inclement 
weather or other natural event do not require reporting to  the MSKCC IRB/PB.  However, 
they must be clearly documented  in the  patient's medical record.  
Prospective  Deviations  
Deviations  to the research  protocol  that involve  an informed  consent  procedure  change 
and/or treatment/pharmacy  alterations that are not allowed by the  protocol require 
prospective  approval  from  the MSKCC  IRB/PB  prior  to the change  being carried  out. 
Participating  sites should  contact  the PCCTC  who will in turn seek approval  from  the MSK 
IRB/PB. Deviations to the research protocol that involve patient eligibility   will not  be 
permitted.  
Retrospective  Deviations  
Deviations that include a change or departure from the research protocol without prior 
approval from the MSKCC IRB/PB are  considered retrospective deviations. Retrospective 
deviations  should be reported to  the PCCTC as  soon as  possible, who  will in turn report the 
deviation  to the MSKCC  IRB/PB  as per MSKCC  guidelines.  
Participating  Site !RB Reporting  
Participating  sites should  report  all deviations  to their institution's  IRB per local  guidelines. 
Approvals/acknowledgments from  the participating  site IRB for protocol  deviations  should 
be submitted  to the  PCCTC  upon  receipt. The PCCTC is responsible for submitting all 
participating  site local  IRB approvals  and/or  acknowledgments  to MSKCC  upon  receipt.  
 
Other  correspondence  
Participating  sites should  submit  other  correspondence  to their  institution's  IRB according 
to local guidelines, and submit copies of that correspondence to the PCCTC.  The PCCTC is 
responsible for submitting all participating site local IRB correspondences  to MSKCC upon 
receipt  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(B)  
Page  64  
  
 
12.6 Document  Maintenance  
The MSKCC PI  and participating  site PI will maintain adequate  and accurate  records  to fully 
document  protocol  implementation and allow data to be subsequently verified.  
The participating sites will ensure that all regulatory documents and participating site IRB 
correspondence are maintained in an on -site regulatory binder and sent to the PCCTC as 
outlined within the protocol. The on -site regulatory binder will be reviewed  by the 
designated study monitor at  monitoring visits. A regulatory binder for each  participating 
site will also be maintained at the PCCTC; this binder may be paper or electronic.  
After  study closure, the participating sites must maintain all  source docum ents, study 
related documents and eCRFs for 7 years.  
 
12.7 Written  Informed  Consent  
Before obtaining consent, members of the study team will review the rationale for the 
treatment program with the patient. The discussion will review the  alternatives available 
(including  hormonal  therapy,  chemotherapy,  or supportive  care as appropriate),  the 
potential benefits of this program, the risks and the probability of their occurrence, and the 
procedures to minimize these risks. Should an AE occur , the provisions available to ensure 
medical intervention will also be reviewed. Why the risks are reasonable in relation to the 
anticipated benefits, incentives, or costs that will or may be incurred as a result of 
participating in the study, as well as t he efforts to maintain confidentiality, will also be 
discussed with the patient.  
Patients will be required to sign and date a statement of informed consent that meets the 
requirements of the  Code of Federal Regulations (Federal Register Vol. 46, No.  17, January 
27, 1981, part 50) and the IRB. The medical record will include a statement that written 
informed consent was obtained  (and document the date that it was obtained)  before the 
patient is enrolled  in the study. The original signed  document will becom e part of the 
patient's  medical  record, a copy will be forwarded  to the lead site/sponsor  pursuant to 
sponsor registration and to the PCCTC and a copy will be sent home with each patient.  
The consent  form  will include  the following:  
• the nature  and objectiv es, potential  toxicities,  and benefits  of the intended  study  
• the length  of therapy  and likely  follow -up required  
• alternatives to  the proposed  therapy (including available standard and investigational 
therapies)  
• the name  of the investigator(s)  responsible  for the  protocol  
• the right of the  patient to accept or refuse treatment and to withdraw from  participation 
in this study  
Text regarding the PCCTC should be added to all institutional informed consent 
documents and sections in th e research authorization/HIPAA  forms (e.g.,  "Prostate 
Cancer Clinical Trials Consortium")  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  65  
  
 
12.8 Protection  of Privacy  
Patients will be informed of the extent to which their confidential health information 
generated  from  this study  may be used  for research  purposes.  After  this discussion,  they 
will be asked to sign a  Notice of Privacy Practice research authorization/HIPAA form. The 
original signed documents  will become  part of the  patient's  medical  records, and each 
patient will receive a copy of the  signed documents. The use and disclosure of protected 
health informa tion will be limited to the individuals described in the research authorization 
form.  The research authorization form must be completed by the principal investigator and 
approved by the  IRB.  
12.9 Terminating  or Modifying  the Study  
AE and laboratory  data from  this trial will be assessed by  the lead site or the sponsor's 
medical  monitor  on an ongoing  basis. SAEs  will be reviewed  as they are  reported  to the lead 
site/sponsor  and the PCCTC,  and the medical  monitor  will make  an assessment  regarding 
the safety  of continuing  or modifying  the study.  This assessment  will be shared  with the 
investigators  either  in writing  or as part of a teleconference.  Should  the assessment of 
either the  lead site/sponsor or  the principal investigator  be that the study  should be 
terminated,  the study  will be closed  to further  accrual.  Patients  who are receiving 
cabazitaxel  or abiraterone  acetate  will be assessed  individually  by the investigator  to see if 
it is in the patients'  best interest  to continue,  which might  be the case for a patient  that is 
responding  to the intervention.  Follow -up safety  assessments  will be performed  for all 
patients who  are terminated from the study prematurely.  
 
12.10  Noncompliance  
If a participating site  is noncompliant with the  protocol  document, accrual privileges may  be 
suspended and/or  contract  payments may  be withheld, until  the outstanding issues  have  been 
resolved.  
 
13. REFERENCES  
1.  Sharma A, Yeow WS, Ertel A, et al. The retinoblastoma tumor suppressor controls androgen 
signaling and human prostate cancer progression.]  Clin Invest. 2010;120(12):4478 -4492. doi: 
10.1172/JCI44239;  10.1172/JCI44239.  
2. Bosco  EE, Wang Y, Xu  H, et  al. The retinoblastoma tumor suppressor  modifies  the therapeutic 
response  of breast  cancer.]  Clin Invest.  2007;117(1):218 -228. doi: 10.1172/JCI28803.  
3. Sharma  A, Comstock  CE, Knudsen ES,  et al. Retinoblastoma  tumor  suppressor  status  is a critical 
determinant of therapeutic response in prostate cancer cells.  Cancer Res. 2007;67(13):6192 - 
6203. doi: 10.1158/0008 -5472.CAN -06-4424.  
4. de Bono JS, Logothetis CJ, Molina  A, et al. Abiraterone  and increased survival in metastatic 
prostate  cancer.  N Engl J Med.  2011;364(21):1995 -2005.  doi: 10.1056/NEJMoa1014618.  
5.  Ryan  CJ, Smith  MR, deBono et  al. Abiraterone  in metastatic  prostate cancer without  previous 
chemotherapy.  N Engl J Med.  2013  Jan 10;368(2):138 -48. doi: 10.1056/NEJMoa1209096. Epub 
2012 Dec 10.  
6. de Bono  JS, Oudard  S, Ozguroglu M,  et al. Prednisone  plus cabazitaxel  or mitoxantrone for 
metastatic  castration -resistant prostate  cancer  progressing  after  docetaxel  treatment:  A 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  66  
  
 
randomised  open -label trial. Lancet.  2010;376(9747):1147 -1154.  doi: 10.1016/S0140 - 
6736(10)61389 -X. 
7.  Halabi S, Lin, C, Kelly, W, et  al. Updated  prognostic model for predicting overall survival  in first­ 
line chemotherapy  for patients  with metastatic  castration -resistant  prostate  cancer.  J Clin 
Oncol. 2014; 32:671 -677. 
7a. Halabi S,  Small EJ,  Kantoff PW,  et al. Prognostic model for predicting survival in  men with 
hormone -refractory metastatic prostate cancer. J Clin One. 2013; 21:1232 -1237.  
8. Jemal  A, Siegel  R, Ward  E, Hao Y, Xu J, Thun  MJ. Cancer  statistics,  2009.  CA Cancer  J Clin. 
2009;59(4):225 -249. doi: 10.3322/caac.20006.  
9. Lytton  B. Prostate  cancer:  A brief  history  and the discovery  of hormonal  ablation  treatment.]  
Ural.  2001;165(6   Pt 1):1859 -1862.  
10. Sowery  RD, So AI, Gleave  ME. Therapeutic options  in advanced prostate  cancer:  Present  and 
future. Curr Ural Rep. 2007;8(1):53 -59. 
11.  Hugh J, Hanson J, Cheang MC, et  al. Breast cancer subtypes and response to docetaxel in node­ 
positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001  trial.]  Clin 
Oneal.  2009;27(8):1168 -1176.  doi: 10.1200/JCO.2008.18.1024.  
12. Kim C, Paik S. Gene -expression -based  prognostic  assays  for breast  cancer.  Nat Rev Clin Oneal.  
2010;7(6):340 -347. doi: 10.1038/nrclinonc.2010.61.  
13.  Hewish M, Lord CJ, Martin SA,  Cunningham  D, Ashworth A.  Mismatch repair deficient  colorectal 
cancer in the era  of personalized treatment. Nat Rev Clin Oneal. 2010;7(4):197 -208. doi: 
10.1038/nrclinonc.2010.18.  
14. Peppercorn J, Perou  CM, Carey  LA. Molecular  subtypes  in breast  cancer  evaluation  and 
management: Divide and conquer. Cancer Invest. 2008;26(1):1 -10. doi: 
10.1080/07357900701784238.  
15. Knudsen  ES, Knudsen  KE. Tailoring  to RB: Tumour  suppressor status  and therapeutic  response.  
Nat Rev Cancer. 2008;8(9):714 -724. doi: 10.1038/nrc2401.  
16. Burkhart  DL, Sage  J. Cellular  mechanisms  of tumour  suppression  by the retinoblastoma  gene.  
Nat Rev Cancer.  2008;8(9):671 -682. doi: 10.1038/nrc2399.  
17. Taylor  BS, Schultz  N, Hieronymus  H, et al. Integrative  genomic  profiling  of human  prostate 
cancer. Cancer Cell. 2010;18(1):11 -22. doi: 10.1016/j.ccr.2010.05.026.  
18. Sun H, Wang  Y, Chinnam M,  et al. E2f binding -deficient  Rb1 protein  suppresses prostate  tumor 
progression in vivo. Proc Natl Acad Sci US A. 2011;108(2):704 -709. doi: 
10.1073/pnas.1015027108.  
19.  Macleod  KF. The RB tumor suppressor: A gatekeeper to hormone independence in prostate 
cancer?  J Clin Invest.  2010;120(12):4179 -4182.  doi: 10.1172/JCI45406;  10.1172/JCI45406.  
20. Ertel  A, Dean  JL, Rui H, et al. RB-pathway  disruption  in breast  cancer:  Differential  association 
with disease subtypes, disease -specific prognosis and therapeutic response. Cell Cycle. 
2010;9(20):4153 -4163.  
21.  Knudsen  KE, Booth D,  Naderi  S, et al. RB-dependent S -phase response  to DNA  damage.  Mo/ Cell 
Biol. 2000;20(20):7751 -7763.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8) 
Page  67  
  
 
22.  Tannock  IF, de Wit R, Berry  WR,  et al.  Docetaxel plus  prednisone  or mitoxantrone  plus 
prednisone for advanced  prostate cancer. N Engl] Med. 2004;351(15):1502 -1512.  doi: 
10.1056/NEJMoa040720.  
23.  http:  //www.jevtana .com/hcp  /dosing/preparation -administration.aspx . Updated  2011. 
Accessed October  /27, 2011.  
24.  http://www.accessdata.fda .gov/drugsatfda  docs/label/2010/201023lbl.pdf . Updated 201 0. 
Accessed October  /27, 2011.  
25. http://www.accessdata.fda .gov/drugsatfda   docs  /label/2011/2  02379lbl.pdf . Updated  2011.  
Accessed  October  27, 2011.  
26.  Scher  HI, Halabi  S, Tannock  I, et al. Design  and end points  of clinical  trials  for patients  with 
progressive prostate cancer and castrate levels of testosterone: Recommendations of the 
prostate cancer clinical trials working group.]  Clin Oneal. 2008;26(7):1148 -1159. doi: 
10.1200/JCO.2007.12.4487.  
MSK  IRB#: 14 -046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page  68  
  
 
APPENDIX  A: PERFORMANCE  STATUS  CRITERIA  
ECOG  Performance  Status  Scale  I   Karnofsky  Performance  Scale   
Grade  Description  I %  Description   
Normal, no complaints, no evidence of 
disease   
 
0  
Normal activity. Fully active, able to 
continue  all pre-disease  performance 
without restriction.  100 
90 Able  to carry  on normal  activity,  minor 
signs or  symptoms of disease  
 Symptoms,  but ambulatory.  Restricted  in 
physically strenuous activity but  80 Normal  activity  with effort,  some  signs  or 
symptoms of disease  
1  
ambulatory  and able to carry  out work  of a 
light or sedentary  nature  (e.g.,  light 
housework, office work).   
70 Cares for  self, unable to carry on normal 
activity or to do active work  
 
 
2 In bed <  50%  of the  time.  Ambulatory and 
capable  of all  self-care but  unable  to carry 
out any  work  activities.  Up and about  more 
than 50% of waking hours.  60 Requires  occasional  assistance  but is able 
to care for  most needs  
so Requires  considerable  assistance  and 
frequent medical care  
 
 
3  
In bed > 50% of the  time.  Capable of  only 
limited  self-care,  confined  to bed or chair  
> 50% of waking  hours.  40 Disabled,  requires  special  care and 
assistance  
30 Severely disabled, hospitalization  indicated. 
Death not imminent . 
 
 
4  
100% bedridden. Completely disabled,  
cannot carry on any self -care, totally 
confined to bed or chair.  20 Very sick,  hospitalization  indicated. Death 
not imminent.  
10 Moribund, fatal processes progressing 
rapidly  
5 Dead  0 Dead  
MSK  IRB#: 14 -046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page  69  
  
 
 
APPENDIX  B: MEDICATIONS  WITH  THE  POTENTIAL  FOR  DRUG -DRUG  INTERACTIONS  
 
CABAZITAZEL  
No formal  clinical  drug -drug  interaction  trials  have  been  conducted  with cabazitaxel.  
Prednisone or prednisolone administered at 10 mg  daily did not  affect the  pharmacokinetics  of 
cabazitaxel.  
Drugs  That  May  Increase  Cabazitaxel  Plasma  Concentrations  
CYP3A4 Inhibitors:  Cabazitaxel is  primarily  metabolized through CYP3A.  Though no  formal drug 
interaction trials have been conducted for cabazitaxel, concomitant administration of  strong  CYP3A 
inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir , nefazodone, 
nelfinavir, ritonavir, saquinavir, telithromycin,  voriconazole) is expected to increase concentrations 
of cabazitaxel. Therefore, co -administration with strong CYP3A inhibitors should be avoided.  
Caution  should be  exercised with  concomitant u se of moderate  CYP3A  inhibitors. 
Drugs That May Decrease Cabazitaxel Plasma Concentrations  
CYP3A4 Inducers: Though no  formal drug interaction trials have been conducted for cabazitaxel, 
the concomitant administration of strong CYP3A inducers (e.g., phenyto in, carbamazepine, 
rifampin, rifabutin, rifapentin, phenobarbital) is expected to decrease cabazitaxel concentrations. 
Therefore, co -administration  with strong  CYP3A inducers should be  avoided.  In addition, patients 
should also refrain from taking St. John's Wort.  
ABIRATERONE  
Based  on in vitro data, abiraterone  is a substrate  of CYP3A4. The effects  of strong CYP3A4  inhibitors 
(e.g.,  ketoconazole,  itraconazole,  clarithromycin,  atazanavir,  nefazodo ne, saquinavir,  telithromycin, 
ritonavir,  indinavir,  nelfinavir,  voriconazole)  or inducers  (e.g.,  phenytoin,  carbamazepine, rifampin, 
rifabutin,  rifapentine, phenobarbital)  on the pharmacokinetics  of abiraterone have  not been 
evaluated,  in vivo. It is recommended  to avoid  or use with caution,  strong  inhibitors  and inducers  of 
CYP3A4 during  abiraterone treatment  
MSK  IRB#: 14 -046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page  70  
  
 
APPENDIX  C: LABORATORY  MANUAL \CORRELATIVE  STUDIES  
 
Please  see the Laboratory  & Correlative  Studies  Manual  
MSK  IRB#: 14 -046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page  71  
  
 
APPENDIX D: STANDARD  OPERATING  PROCEDURES  FOR ULTRASOUND \CT-GUIDED 
BIOPSY OF METASTATIC PROSTATE CANCER LESION  
Please  see the Laboratory  & Correlative  Studies  Manual  
MSK  IRB#: 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8)  
Page  72  
  
 
APPENDIX  E: LISTING  OF EXPECTED/UNEXPECTED  ADVERSE  EVENTS  
Comprehensive  Adverse  Events  and Potential  Risks  (CAEPR)  List for Cabazitaxel  and 
Abiraterone.  
 
The Comprehensive  Adverse Event  and Potential Risks  (CAEPR) list  provides  a single,  complete  list 
of reported and potential adverse events associated with an agent using a uniform  presentation  of 
events by body system. In addition to the comprehensive list, a  subset, the Agent Specific Adverse 
Event List (ASAEL), appears in  a separate column.  The ASAEL contains events that  are considered 
expected for  expedited reporting purposes only.  Refer  to the  NCI/CTEP Guidelines: Adverse Event 
Reporting  Requirements  available  athttp://ctep.cancer.go v/reporting/adeers.html  for further 
clarification.  
Adverse  Events  in .::5%  of patients  receiving  cabazitaxel  plus prednisone  
 
 
 Cabazitaxel  plus prednisone  
N=371  
Adverse  Reaction  All Grades  
% Grades  3-4 
% 
Blood  and lymph  
Neutropenia  
Febrile neutropenia 
Anemia  
Leukopenia  
Thrombocytopenia  94 
7 
98 
96 
48 82 
7 
11 
69 
4 
Cardiac  
Arrhythmia  5 1 
GI Disorders 
Diarrhea  
Nausea 
Vomiting 
Constipation 
Abdominal  pain 
Dyspepsia  47 
34 
22 
20 
17 
10 6 
2 
2 
1 
2 
0 
General 
Fatigue 
Asthenia 
Pyrexia  
Peripheral edema 
Mucosal  inflammation  
Pain 37 
20 
12 
9 
6 
5 5 
5 
1 
<1 
<1 
1 
Infections  
Urinary  tract infection   
8 2 
Weight  decreased  9 0 
Metabolism  and nutrition    
MSK  IRB# : 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(B)  
Page  73  
  
 
Anorexia  
Dehydration  16 
5 <1 
2 
Musculoskeletal  
Back pain 
Arthralgia 
Muscle  spasms  16 
11 
7  
4 
1 
0 
Nervous  system  
Peripheral neuropathy 
Dysgeusia  
Dizziness 
Headache   
13 
11 
8 
8 <1 
0 
0 
0 
Renal  and Urinary  
Hematuria  
Dysuria  17 
7 2 
0 
Respiratory  
Dyspnea 
Cough  12 
11 1 
0 
Skin  
Alopecia  10  
0 
Vascular  
Hypotension   
5 <1 
MSK  IRB#: 14-046 A(12),  Approval  Date:  31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI: c12-108 
IRB#:  14-046 A(8)  
Page  74  
  
 
Adverse  reactions  due to abiraterone  acetate  
 
 
 Abiraterone with 
Prednisone  
. (N=791)  Placebo with 
Prednisone  (N=394)  
 All IGrad e 3-1All IGrade  3-4 Grades1  4 Grades  
Adverse  reaction  % 1% 1% 1% 
Musculoskeletal  and connective  tissue  disorders  
Joint  swelling/  discomfort2 29.5 4.2 23.4 4.1 
Muscle  discomfort3 1 26.2 3.0 23.1 2.3 
General  disorders  
Edema4 26.7 1.9 18.3 0.8 
Vascular  disorders  
Hot flush  19.0 0.3 16.8 0.3 
Hypertension  1 8.5 1.3 6.9 0.3 
Gastrointestinal  disorders  
Diarrhea  17.6 0.6 13.5 1.3 
Dyspepsia  1 6.1 0 3.3 0 
Infections  and infestations  
Urinary  tract infection  11.5 2.1 7.1 0.5 
Upper  respiratory  tract  
infection  5.4 0 2.5 0 
Respiratory,  thoracic  and mediastinal  disorders  
Cough  10.6 0 7.6 0 
Renal  and urinary  disorders  
Urinary  frequency  7.2 0.3 5.1 0.3 
Nocturia  1 6.2 0 4.1 0 
Cardiac  disorders  
Arrhythmias  7.2 1.1 4.6 1.0 
Chest  pain or chest  
discomfort6 3.8 0.5 2.8 0 
Cardiac  failure7 2.3 1.9 1.0 0.3 
1 Adverse  events  graded  according  to CTCAE  version  4.0 
2 Includes  terms  Arthritis, Arthralgia,  Joint  swelling,  and Joint  stiffness,  
3 Includes  terms  Muscle  spasms,  Musculoskeletal  pain,  Myalgia,  Musculoskeletal  discomfort, 
and Musculoskeletal stiffness  
4 Includes  terms  Edema,  Edema  peripheral,  Pitting  edema,  and Generalised  edema  
5 Includes terms Arrhythmia, Tachycardia, Atrial fibrillation, Supraventricular tachycardia, 
Atrial tachycardia,  Ventricular tachycardia,  Atrial flutter, Bradycardia,  Atrioventricular  block 
complete, Conduction disorder, and Bradyarrhythmia . 
6 Includes terms Angina p ectoris, Chest pain,  and Angina unstable . Myocardial infarction or 
ischemia  occurred more  commonly  in the placebo  arm than in the ZYTIGA  arm (1.3%  vs. 1.1% 
respectively) . 
7 Includes  terms  Cardiac failure,  Cardiac  failure  congestive, Left ventricular dysfunction, 
Cardiogenic shock, Cardiomegaly, Cardiomyopathy,  and Ejection fraction decreased  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 75  
  
 
 
 
APPENDIX  F: GLOSSARY  OF ABBREVIATIONS  AND  ACRONYMS  
 
 
AdEERS  Adverse  Event  Expedited  Reporting  System  
ADR adverse  drug reaction  
AE adverse  event  
ALT alanine  aminotransferase  
ANC absolute  neutrophil  count  
APTT  activated  partial thromboplastin  time 
AR androgen  receptor  
ASAEL  Agent  Specific  Adverse  Event  List 
AST aspartate  aminotransferase  
AUC area  under  the plasma  concentration -time curve  
Bid bis in  die (twice  a day) 
BLQ below  limit of quantification  
BMI body  mass  index  
BP blood  pressure  
BSA Body  Surface  Area 
BUN blood  urea  nitrogen  
C Celsius  
cDNA  Circulating  DNA  
Ca++  calcium  
CAEPR  Comprehensive  Adverse  Event  and Potential  Risks  
CBC complete  blood  count  
CDUS  Clinical Data  Update  System  
CFR Code  of Federal  Regulations  
Cl confidence  interval  
Cl- chloride  
Cler creatinine  clearance  
Cm centimeter  
Cmax  maximum  plasma  concentration  
CNS central  nervous  system  
CR complete  response  
CRF case  report  form 
CRPC  castration  resistant  prostate  cancer  
CT computerized  tomography  
CTC circulating  tumor  cell 
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 76  
  
 
CTCAE  Common  Terminology  Criteria  for Adverse  Events  
CTEP  Cancer  Therapy  Evaluation  Program  
CV coefficient  of variation  
CYP cytochrome  p-450 
dL deciliter  
DHEA  dehydroepiandrosterone  
DLT dose -limiting  toxicity  
DNA Deoxyribo  Nucleic  Acid 
DSM  data and safety  monitoring  
ECOG  Eastern  Cooperative  Oncology  Group  
EKG electrocardiogram  
F bioavailability  
FDA Food  and Drug  Administration  
FISH fluorescence  in situ hybridization  
FSH follicle  stimulating  hormone  
GCP good  clinical  practice  
GFR glomerular  filtration  rate 
HIPAA  Health  Insurance  Portability  and Accountability  Act 
HR heart  rate 
ICH International  Conference  on Harmonisation  
IEC Independent  Ethics  Committee  
IHC immunochemical  
IND investigational  new drug 
INR international  normalized  ratio 
IRB Institutional  Review  Board  
IV intravenous  
LC liquid  chromatography  
LDH lactate  dehydrogenase  
Ln natural  logarithm  
LOCF  last observation  carried  forward  
LOI letter  of intent  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
MIC minimum  inhibitory  concentration  
MRI magnetic  resonance  imaging  
MSKCC  Memorial  Sloan Kettering Cancer  Center  
MS mass  spectrometry  
MTD  maximum  tolerated dose  
N number  of subjects  or observations  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 77  
  
 
NA not applicable  
NCI National  Cancer  Institute  
NIH National  Institutes  of Health  
PCCTC  Prostate  Cancer  Clinical  Trials  Consortium  
PCRP  Department  of Defense Prostate  Cancer  Research  Program  
PD progressive  disease  
PET positron emission  tomography  
PFS progression -free survival  
Pl principal  investigator  
PK pharmacokinetics  
PCa Prostate  Cancer  
PO per os (by mouth)  
POD Progression  of Disease  
PR partial  response  
PSA prostate -specific  antigen  
PSA-DT prostate -specific  antigen  doubling  time 
PT prothrombin  time 
PTT partial  thromboplastin  time 
Qd quaque  die (every  day) 
QOL quality  of life 
RBC red blood  cell 
RB+ Retinoblastoma  tumor  suppressor+  
RB­ Retinoblastoma  tumor  suppressor  - 
RECIST  Response Evaluation  Criteria  in Solid  Tumors  
RP radical  prostatectomy  
RSA Research  Study  Assistant  
SAE serious  adverse  event  
SC subcutaneous  
SD standard  deviation  
SD stable  disease  
SOP Standard  Operating  Procedures  
T temperature  
tl/2 terminal  half-life 
T time 
Tid ter in die (3 times  a day) 
TX treatment  
ULN upper  limit of normal  
Vss volume  of distribution  at steady -state  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 78  
  
 
WBC 
WHO  white blood  cell 
World  Health  Organization  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 79  
  
 
APPENDIX  G. PILL  DIARY  
Please  see the attached  patient  pill diary.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 80  
  
 
 
 
APPENDIX H:  STANDARD  OPERATING  PROCEDURE  FOR  SHIPMENT  OF CLINICAL 
SAMPLES  
Please  see the Laboratory  & Correlative  Studies  Manual  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 81  
  
 
APPENDIX  I: 1 ST SAE REPORT  
Sanofi  ISS Serious  Adverse  Event  Cover  Page  
 
Fax: 
To: 
I 
I 
I Investigator  Sponsored  Studies  (ISS)  SAE Report 
US Pharmacovigilance  
 
VisionTracker  # / ClubNet#:  CABAZL06066  
Study  Title:  An Exploratory Randomized  Phase  II Multicenter  Trial  of 
Abiraterone Acetate with or without Cabazitaxel  in 
Treatment of  Metastatic Castration Resistant Prostate Cancer  
PI Name:  Susan  Slovin,  MD 
Causality:  All serious,  related  adverse  events will  be reported  and documented  on MedWatch  Form  
FDA 3500A  
(http://www.fda .gov/downloads  /AboutFDA/ReportsManualsForms/Forms/UCM163919 . 
pd_f) and forwarded  directly to sanofi -aventis Pharmaceuticals . This includes serious, 
related, labeled  (expected) and serious, related, unlabeled  (unexpected)  adverse 
experi ences.  
For Comparator Drugs / Secondary Suspects (Concomitant 
Medications), all serious adverse experiences will be  
forwarded to the product manufacturer.  
Check  one:  
I Unrelated :  The adverse  event  is clearly  NOT  related.  
 Unlikely  to be related : The adverse  event  is doubtfully  
related.  
IPossibly  related : The adverse  event  may  be related.  
IProbably  related : The adverse  event  is likely  related.  
I Definitely  related :  The adverse  event  is clearly  related.  
Fax: 908-203-7783  or Email  to: USPVmailbox@sanofi .com 
Date:  
 Pages:  
From:  
 Phone:  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 82  
  
 
 
 
APPENDIX  J: PCCTC  SERIOUS  ADVERSE  EVENT  REPORT  FORM  
 
Please  see the supplemental  PCCTC  Serious  Adverse  Event  Form  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 83  
  
 
 
APPENDIX  K: PCCTC  BONESCAN  ASSESSMENT  TOOL  
Use the attached  Appendix  Bone  Scan  PCCTC  Tool.  
MSK  IRB# : 14-046 A(12),  Approval  Date : 31-0ct-2022  
Cabazitaxel and Abiraterone Acetate 
MSKCC  PCCTC  LOI:  c12-108 
IRB#:  14-046 A(B)  
Page 84  
  
 
APPENDIX  L: HALABI  NOMOGRAM  RISK  
 
Use the following  link for the Halabi Nomogram and  see instructions  below  for completion: 
https://www.cancer.duke.edu/Nomogram  / firstlinechemotherapy.html  
1. Accept  terms  of the Disclaimer  
2. For Display  Output,  select  "Yes"  
3. For Risk Group  Classification,  select  "2 Groups"  
4. Complete  the remaining  questions  as according  to the patient's  source  documentation  
5. DO NOT  provide  patient  ID. 
6. Click  "Validate"  once complete  
7. Click  "PDF  Results  File".  
8. Print  the results and write in the patient's MRN as  the patient ID  for submission to the 
patient's EMR, for source documentation  